	Link with violence

Antisocial

Social norms	No specific reference within literature.

Deceitfulness	No specific reference within literature.

Impulsivity	Related to more violent assaults [41].Did not directly predict aggression once emotional dysregulation was controlled for [40].Impulsivity related to history of persistent violence [27]

Aggressiveness	Disturbed batterers more physically aggressive [7].Aggressiveness related to ASPD and NPD diagnoses. In BPD aggressiveness linked to poor impulse control. [19].

Reckless	Related to more violent assaults [41].

Irresponsibility	No specific reference within literature.

Lack remorse	No specific reference within literature.

Borderline

Avoid abandonment	Avoidant attachment predicted severity of physical partner violence mediated by interpersonal difficulties [31].Female offenders have greater number of traumatic experiences and less secure attachment styles [22].ASPD and BPD diagnoses mediated path between by avoidant attachment intimate partner violence [34].

Unstable relationships	See ‘Avoid Abandonment’.

Identity disturbance	No specific reference within literature.

Impulsivity	See ‘Impulsivity’ under Antisocial diagnosis.

Suicidal behavior	No specific reference within literature.

Affective instability	Emotional Dysregulation predicted physical assault [40].

Emptiness	No specific reference within literature.

Anger	Impulsivity predicted physical aggression and trait anger. Trait anger mediates relationship between impulsivity and physical aggression. [42].

Paranoid ideation	Disturbed batterers higher levels of paranoid ideation [7].

Narcissistic

Grandiose	Link between experience grandiose delusions and serious violence. Stronger link to violence when associated with elation or anger [49].

Fantasies of success	No specific reference within literature.

Is “special”	See ‘Grandiose’.

Excessive admiration	No specific reference within literature.

Sense of entitlement	Evidence of inflated sense of entitlement linked to violent offenders. When violated more likely to be violent [18]

Exploitative	No specific reference within literature.

Lacks empathy	Violent offenders have reduced ability to recognise facial emotions [41].Poor perspective taking exacerbated anger arousal [9].Violent offender have poorer empathy [7].

Envious	No specific reference within literature.

Arrogant	No specific reference within literature.

	Link with violence

Grandiose	Link between experience grandiose delusions and serious violence. Stronger link to violence when associated with elation or anger [49].

Fantasies of success	No specific reference within literature.

Is “special”	See ‘Grandiose’.

Excessive admiration	No specific reference within literature.

Sense of entitlement	Evidence of inflated sense of entitlement linked to violent offenders. When violated more likely to be violent [18]

Exploitative	No specific reference within literature.

Lacks empathy	Violent offenders have reduced ability to recognise facial emotions [41].Poor perspective taking exacerbated anger arousal [9].Violent offender have poorer empathy [7].

Envious	No specific reference within literature.

Arrogant	No specific reference within literature.


	Patients (n)	Coverage (106 reads)	Cassette exons	Competing 5′ splice sites	Competing 3′ splice sites	Retained introns	Constitutive introns	Constitutive junctions	Retained intron ratio

Thyroid	58	83 (11)	533	132	177	174	488	332	0.66 (2.4)


Characteristic	Ranking from electronic survey	Ranking from paper survey

Impact on care	1	2

Strength of supporting evidence	2	1

Local health needs of patients/clients	3	3

Costs associated with new ways of working	4	4

Local expertise	5	5

Meeting minimum standards	6	6

National or local priority	7	7

Characteristic	Ranking from electronic survey

Impact on care	1

Strength of supporting evidence	2

Local health needs of patients/clients	3

Costs associated with new ways of working	4

Local expertise	5

Meeting minimum standards	6

National or local priority	7

Ranking from paper survey

2

1

3

4

5

6

7


Property	Explanation

Citation-related properties

occursInChecklist	Reference to a species checklist

auctorumYear	The year of original publication

completeAuctorumString	Author name(s) expressed according

	to the established practices of taxonomy

Name-related properties

hasNonvalidName	Expresses synonyms, homonyms

	and orthographic variants of a valid

	scientific name

hasVernacularName	The common name equivalents for

	the scientific names

hasNomenclaturalCode	Specifies the set of rules that are applied

	(ICN [55] or ICZN [56])

hasVernacularNameStatus	Expresses whether a common name is

	accepted or an alternative one

rdf:type	Expresses the hierarchical level in

	a classification. The ranks are obtained

	from TDWG Taxon Rank LSID Ontology [57].

	Every taxon is an instance of a specific

	taxonomic rank and the class

	TaxonInChecklist (Figure 3).

Property	Explanation

	scientific name

hasVernacularName	The common name equivalents for

	the scientific names

hasNomenclaturalCode	Specifies the set of rules that are applied

	(ICN [55] or ICZN [56])

hasVernacularNameStatus	Expresses whether a common name is

	accepted or an alternative one

rdf:type	Expresses the hierarchical level in

	a classification. The ranks are obtained

	from TDWG Taxon Rank LSID Ontology [57].

	Every taxon is an instance of a specific

	taxonomic rank and the class

	TaxonInChecklist (Figure 3).


Item*	Affirmative responses (%)**	Item calibration***	SE****	Item infit	Item outfit

AD1 Worried food would run out	48.7	3.45	0.078	0.76	1.85

AD2 Food ran out; did not have money for more	53.1	2.86	0.085	0.95	1.47

AD3 Could not afford to eat nutritious meal	50.9	3.17	0.081	0.97	4.20

AD4 Cut size of meal or skipped meal	26.7	5.90	0.077	1.03	1.80

AD5 Ate less than thought he/she should	21.3	6.58	0.084	0.90	1.62

AD6 Hungry but did not eat	13.2	7.93	0.101	0.76	0.81

AD7 Lost weight	10.3	8.60	0.113	1.09	2.03

AD8 Did not eat for whole day	7.2	9.51	0.134	1.05	1.14

Mean		6.00

Standard deviation		2.44

Discrimination parameter		1.00

Number of cases*****	2,003	1,241	1,241	1,241	1,241

Item*	Affirmative responses (%)**	Item calibration***	SE****	Item infit	Item outfit

AD1 Worried food would run out	48.7	3.45	0.078	0.76	1.85

AD2 Food ran out; did not have money for more	53.1	2.86	0.085	0.95	1.47

AD3 Could not afford to eat nutritious meal	50.9	3.17	0.081	0.97	4.20

AD4 Cut size of meal or skipped meal	26.7	5.90	0.077	1.03	1.80

AD5 Ate less than thou	21	6		0.90	1

ght he/she should	.3	.58	0.084		.62

AD6 Hungry but did not eat	13.2	7.93	0.101	0.76	0.81

AD7 Lost weight	10.3	8.60	0.113	1.09	2.03

AD8 Did not eat for whole day	7.2	9.51	0.134	1.05	1.14

Mean		6.00

Standard deviation		2.44

Discrimination parameter		1.00

Number of cases*****	2,003	1,241	1,241	1,241	1,241


	FDC (n = 54)

Age, mean ± SD	45 ± 8.7

Asian ethnicity, n (%)a	51 (94.4)

Male gender, n (%)	52 (96.3)

Weight (kg), mean ± SDb	59.2 ± 9.8

Weight bands, nb

< 35 kg	0

35–54 kg	13

> 54 kg	25

Height (cm), mean ± SDc	165.2 ± 7.8

Smokers, n (%)	19 (35.2)

Hypertension, n (%)	11 (20.4)

Vitamin D level, mean ± SDd	19.5 ± 22.5

HbA1c, mean ± SD	10.6 ± 2.5

AFB load, n (%)

1+	10 (18.5)

2+	19 (35.2)

3+	21 (38.9)

Anti-TB dose (mg/kg), mean ± SD

Isoniazid	4.8 ± 0.5

Rifampin	9.6 ± 1.1

Pyrazinamide	25.6 ± 2.6

Ethambutol	17.5 ± 2

Patients received metformin, n (%)	38 (70.4)


Characteristics	Experimental mean (SD)	Control mean (SD)	p	F

Age (Years)	69.95 (6.73)	73.20 (6.48)	0.13	2.36

Education (Years)	13.37 (3.27)	12.85 (3.36)	0.62	0.23


Groups	Normoglycemic(n = 10)	Hyperglycemic(n = 10)	Hyperglycemic + vitamin C (n = 9)

Sperm number in the cauda epididymis (×106)	111.00 [90.00 - 131.00] a	40.16 [33.05 - 71.00] b	43.00 [42.63 - 73.80] ab

Sperm transit time in the cauda (days)	3.43 [3.30 - 4.65] a	1.56 [1.25 - 2.70] b	2.14 [1.72 - 2.88] ab


Plant	Feedstock	Volume of AD digesters (m3)	Dry matter content in digesters (%)	Organic loading in digesters (kg/day⋅m3)	Methane content in biogas (%)	Installed CHP power (kW)	Electricity generation (MWh/year)	Electricity consumption (MWh/year)	Heat generation (MWh/year)	Heat consumption by AD (MWh/year)

Plant 1	• Pig slurry• Tomato peel and seeds• Maize silage	1650	8.7	0.92	52.8	230	1945	173	2549	809

Plant 2	• Pig slurry• Maize silage	2250	10.6	1.07	52.6	300	2429	206	3184	814

Plant 3	• Pig slurry• Maize silage• Maize ear silage	2000	9.7	0.98	52.7	300	2505	276	3514	799

Plant 4	• Maize silage	2 × 2750	10.7	3.40	52.1	999	7972	717	8771	2505

Plant 5	• Cow slurry	1850	8.5	0.58	56.0	100	781	86	1095	547


Medicine	MIC (mg/L)

AMPH-B	0.25

5-FC	<=0.12

MCZ	0.06

FLCZ	8

ITCZ	0.12

MCFG	<=0.015

VRCZ	0.25


	Men (n = 98)

CCsa	Same category

Energyb	0.58	34

Water content	0.43	33

Protein	0.53	46

The sum of amino acid residues	0.58	31

Total fat	0.49	33

Total fat in % energyb	0.50	23

Saturated fatty acid	0.49	34

Monounsaturated fatty acid	0.50	34

Polyunsaturated fatty acid	0.46	36

n-3 PUFA	0.50	27

n-6 PUFA	0.45	35

Triacylglycerol equivalents	0.49	32

Cholesterol	0.61	36

Carbohydrate	0.60	44

Total dietary fiber	0.58	46

Water soluble fiber	0.56	50

Water insoluble fiber	0.58	41

Sodium	0.58	39

Potassium	0.68	43

Calcium	0.61	38

Magnesium	0.67	41

Phosphorus	0.61	35

Iron	0.75	46

Zinc	0.66	38

Copper	0.69	43

Manganese	0.61	45

Iodine	0.44	40

Selenium	0.59	37

Chromium	0.50	31

Molybdenum	0.68	41

Retinol	0.41	47

α-carotene	0.53	43

β-carotene	0.55	40

Cryptoxanthin	0.46	30

Beta carotene equivalents	0.55	41

Retinol equivalents	0.50	41

Vitamin D	0.57	33

α-tocopherol	0.57	44

β-tocopherol	0.51	35

γ-tocopherol	0.37	27

δ-tocopherol	0.49	41

Vitamin K	0.60	40

Vitamin B1	0.56	37

Vitamin B2	0.66	38

Niacin	0.65	43

Vitamin B6	0.65	43

Vitamin B12	0.63	41

Folate	0.74	43

Pantothenic acid	0.60	40

Biotin	0.66	43

Vitamin C	0.71	37

Daidzein	0.52	38

Genistein	0.52	39

Ethanol	0.89	64

Median		39


	Q1	Q2	Q3	Q4

(Pre)	(Pos)	(Pre)	(Pos)	(Pre)	(Pos)	(Pre)	(Pos)

Min	1	3	1	3	1	3	1	3


Diagnosis	Intervention	Number of Patients	Reference

Evidence from Pediatric Studies

msk pain/soft tissue injury	analgesic	17	Clark 2003[10]

Asthma exacerbation	inhaled β-agonist	12	Travers 2001[11]

radial fracture	reduction & cast	10	McLauchlan 2002[12]

otitis media	PO antibiotics	10	Kozyrskyj 2000[13]

dehydration (failed PO rehydration)	IV rehydration	6	Atherly-John 2002[14]

bronchiolitis	salbutamol	6	Kellner 2000[15]

dehydration	PO rehydration	5	Atherly-John 2002[14]

urinary tract infection	PO antibiotics	5	Hoberman 1999[16]

constipation	suppository/enema	5	Dashshan 1999[17]

laceration	sutures	4	Barnett 1998[18]

croup	PO steroids	4	Ausejo 2000[19]

suspected occult bacteremia	IM/IV antibiotics	3	Bass 1993[20]

tonsillitis	PO antibiotics	3	Del Mar 2000[21]

urticaria	cetirizine	2	Simons 2000[22]

Kawasaki Syndrome	IVIG & ASA	2	Newburger 1986[23]

alcohol intoxication	intubation	2	Gausche-Hill 2000[24]

generalized tonic-clonic seizure in known epileptic	increase clobazam dose	1	Booth 1998[25]

radial head subluxation	reduction by hyperpronation	1	Macias 1998[26]

epistaxis	silver nitrate	1	Ruddy 1991[27]

behavior problems	referral for counselling	1	Dishion 1995[28]

bronchiolitis	racemic epinephrine	1	Menon 1995[29]

viral conjunctivitis	polysporin ointment	1	Isenberg 2002[30]

laceration	tissue glue	1	Barnett 1998[18]

constipation	polyethylene glycol	1	Dashshan 1999[17]

dog bite	IV antibiotics & debridement	1	Medeiros 2001[31]

burn	delayed graft	1	Desai 1991[32]

reflux esophagitis	conservative reflux measures	1	Craig 2004[33]

pain (following MVC trauma)	morphine infusion	1	Hendrickson 1990[34]

reflux esophagitis	ranitidine	1	Cucchiara 1993[35]

varicella zoster	supportive care	1	Klassen 2002[36]

atopic dermatitis	hydrocortisone cream	1	Alonso 1999[37]

meningitis exposure (H flu)	PO antibiotics	1	Daum 1981[38]

dislocated patella	relocation under sedation	1	Nikku 1997[39]

Evidence from Adult Studies

migraine headache	metoclopramide	3	Colman 2003[40]

proximal humerus fracture	cast & sling	3	Gibson 2003[41]

ankle fracture	cast	2	Phillips 1985[42]

gastritis	antacids	1	Moayyedi 2003[43]

clavicle fracture	sling	1	Andersen 1987[44]

prozac overdose (2 hours previous)	supportive care	1	Yeates 2000[45]

tibial fracture	internal fixation	1	Wyrsch 1996[46]

epididymitis	PO antibiotics	1	Redfern 1984[47]

panic attack	sublingual short-acting benzodiazepine	1	Dunner 1986[48]

aphthous ulcers	viscous lidocaine	1	Saxen 1997[49]

fracture T12 vertebrae	T11–12 instrumentation & fusion	1	Shen 2001[50]

aggression	haloperidol & lorazepam	1	Gillies 2001[51]

tibial fracture	reduction & cast	1	Abdel-Salem 1991[52]

acetaminophen overdose	N-acetylcysteine	1	Brok 2002[53]

gastrostomy tube fell out	insertion of foley catheter	1	Kadakia 1994[54]

increased intracranial pressure	mannitol	1	Schierhout 2003[55]

migraine headache	NSAID	1	Bussone 1999[56]

Diagnosis	Intervention	Number of Patients	Reference

increased intracranial pressure	mannitol	1	Schierhout 2003[55]

migraine headache	NSAID	1	Bussone 1999[56]


Category/name	Function	Change (x-fold)

Cellular defense

 HSP27	Protein stabilisation	++

Apoptosis/degeneration

 Cathepsin Z	Lysosomal proteolysis	++

Proliferation

 Annexin	Growth factor	++

Migration

 Cofilin	Actin turnover	+++

 Tropomodulin 3	Actin turnover	++++++

 CLIM1	Actin kinase adaptor	++++++

 Galectin	Cell to cell interaction	++

 β-Hexosaminidase β-subunit	Glycosidasis	++++++

Metabolism

 Pyruvate kinase 3	Glycolysis	−

 Enolase 1	Glycolysis	−

Nuclear transport

 Ran-binding protein 1	RanGAP activity	++

 elF5A	Cofactor in nuclear export	++++++

Translation

 CRHSP-24	Translation regulating protein	++++++

Category/name	Function	Change (x-fold)

Galectin	Cell to cell interaction	++

β-Hexosaminidase β-subunit	Glycosidasis	++++++

Metabolism

Pyruvate kinase 3	Glycolysis	−

Enolase 1	Glycolysis	−

Nuclear transport

Ran-binding protein 1	RanGAP activity	++

elF5A	Cofactor in nuclear export	++++++

Translation

CRHSP-24	Translation regulating protein	++++++


Patient	Location of sample	Size of sample(Average;mm2)	Number of samples taken

P01	Central and peripheral	30	3

P02	Central	24	4

P03	Central	40	3

P04	Central and peripheral	20	4

P05	Central	24	3

P06	Central	80	3

P07	Central and peripheral	66	2

P08	Central and peripheral	72	3


	All patientsN= 14	Survivorsn= 7	Nonsurvivorsn= 7	Pvalue

Characteristics at ICU admission

Age	32 (22–51)	23 (21–44)	48 (30–58)	0.14

Male sex	8	4	4	1.00

CCI	2 (2–2)	2 (2–2)	2 (2–4)	0.48

SAPS II	51 (42–65)	56 (43–63)	45 (39–68)	0.90

Prior allogeneic stem cell transplantation	4	0	4	<0.01

Days from diagnosis of HM to ECMO	87 (6–907)	0 ((−1)–116)	759 (69–1,228)	0.04

Days from ICU admission to ECMO	2 (0–3)	1 (0–2)	3 (1–11)	0.08


	Sham-vehicle (pg/mL)	Sham-EFX (pg/mL)	TBI-vehicle (pg/mL)	TBI-EFX (pg/mL)	TBI-vehicle vs. TBI-EFX

	Ipsilateral	Contralateral	Ipsilateral	Contralateral	Ipsilateral	Contralateral	Ipsilateral	Contralateral	% decrease (ipsilateral side)

IL-10	25.99 ± 1.60	24.13 ± 1.67	19.94 ± 2.04	19.66 ± 4.35	35.29 ± 4.98	17.52 ± 2.82	28.48 ± 2.45	23.12 ± 0.83	ns

Macrophage-attracting chemokines

MIP-1α	1.71 ± 1.01	0.04 ± 0.04	2.64 ± 1.3	0.00 ± 0.00	90.42 ± 25.47***	0.00 ± 0.00	36.99 ± 4.51*	0.24 ± 0.21	41

MCP-1	7.50 ± 1.97	4.30 ± 0.63	12.82 ± 5.16	4.25 ± 0.64	93.82 ± 21.66***	5.53 ± 0.97	53.00 ± 7.45*	6.34 ± 1.55	56


		Enrichment score+	Protein count (%)	Protein ID	P value

Biological process	Regulation of response to external stimulus	2.3	3 (27.27)	AHSG, C3, HRG	4.69e-3

	Cellular iron ion homeostasis	2.13	3 (27.27)	HAP, HPX, TF	1.81e-4

	Iron ion homeostasis	2.13	3 (27.27)	HAP, HPX, TF	2.45e-4

	Cellular di-, tri-valent inorganic cation homeostasis	2.13	3 (27.27)	HAP, HPX, TF	9.34e.3

	Di-, tri-valent inorganic cation homeostasis	2.13	3 (27.27)	HAP, HPX, TF	1.03e-2

	Cellular cation homeostasis	2.13	3 (27.27)	HAP, HPX,TF	1.16e-2

Molecular function	Endopeptidase inhibitor activity	2.3	3 (27.27)	AHSG,C3, HRG	3.32e-3

	Peptidase inhibitor activity	2.3	3 (27.27)	AHSG, C3, HRG	3.69e-3

	Enzyme inhibitor activity	2.3	3 (27.27)	AHSG, C3, HRG	1.11e-2

Cellular component	Extracellular region	8.11	11 (100)	A1BG, AHSG, APOA1, AZGP1, C3, FGG, HAP, HPX, HRG, LRG1, TF	2.66e-11

	Secretory granule	2.31	4 (36.36)	APOA1, FGG, HRG, TF	3.06e-4

	Cytoplasmic membrane-bounded vesicle	2.31	4 (36.36)	APOA1, FGG, HRG, TF	7.58e-3

	Membrane-bounded vesicle	2.31	4 (36.36)	APOA1, FGG, HRG, TF	8.29e-3

	Cytoplasmic vesicle	2.31	4 (36.36)	APOA1, FGG, HRG, TF	1.16e-2

		Enrichment score+	Protein count (%)	Protein ID	P value

Biological process	Regulation of response to external stimulus	2.3	3 (27.27)	AHSG, C3, HRG	4.69e-3

	Cellular iron ion homeostasis	2.13	3 (27.27)	HAP, HPX, TF	1.81e-4

	Iron ion homeostasis	2.13	3 (27.27)	HAP, HPX, TF	2.45e-4

	Cellular di-, tri-valent inorganic cation homeostasis	2.13	3 (27.27)	HAP, HPX, TF	9.34e.3

	Di-, tri-valent inorganic cation homeostasis	2.13	3 (27.27)	HAP, HPX, TF	1.03e-2

	Cellular cation homeostasis	2.13	3 (27.27)	HAP, HPX,TF	1.16e-2

Molecular function	Endopeptidase inhibitor activity	2.3	3 (27.27)	AHSG,C3, HRG	3.32e-3

	Peptidase inhibitor activity	2.3	3 (27.27)	AHSG, C3, HRG	3.69e-3

	Enzyme inhibitor activity	2.3	3 (27.27)	AHSG, C3, HRG	1.11e-2

Cellular component	Extracellular region	8.11	11 (100)	A1BG, AHSG, APOA1, AZGP1, C3, FGG, HAP, HPX, HRG, LRG1, TF	2.66e-11

	Secretory granule	2.31	4 (36.36)	APOA1, FGG, HRG, TF	3.06e-4

	Cytoplasmic membrane-bounded vesicle	2.31	4 (36.36)	APOA1, FGG, HRG, TF	7.58e-3

	Membrane-bound	2.31	4 (3	APOA1,	8

		Enrichment score+	Protein count (%)	Protein ID	P value

	ed vesicle		6.36)	 FGG, HRG, TF	.29e-3

	Cytoplasmic vesicle	2.31	4 (36.36)	APOA1, FGG, HRG, TF	1.16e-2


 	 	Assessment

Outcomes	Measures	t1	t2	t3	t4

Self-management competence (primary outcome)	Health education impact questionnaire heiQ, German version [29]. Subscales Self-monitoring and insight, Skill and technique acquisition	X	X	X	X

Kansas City Cardiomyopathy Questionnaire KCCQ, German version [30]. Subscale self-efficacy	X	X	X	X

Determinants of behavior:

Intention, action and coping planning, action control	HAPA-scales [31,32]	X	X	X	X

Medication beliefs	Beliefs about Medicine Questionnaire BMQ-D [33], German version	X	X	X	X

Self-management behavior:

Symptom control	Questionnaire will be developed by our research group	X	---	X	X

Physical activity	Godin Leisure-Time Exercise Questionnaire [34], German modified version	X	---	X	X

Medication adherence	Medication Adherence Report Scale MARS-D, German version [35]	X	---	X	X

Health-related quality of life (disease specific)	Kansas City Cardiomyopathy Questionnaire KCCQ, German version [30]	X	X	X	X

Treatment satisfaction	Short questionnaire developed by our research group [36]	---	X	---	---


	Hypermethylated	Hypomethylated

n	3925	4615

CpG island location	CpG islands	Non-CGI

Genomic location	TSS, 1st exon	Gene body, outside genes

Associated genes	1832	2057

GO function terms	36	27

GO process terms	265	53

Canonical pathways (IPA)	19	3

Transcription factors	24	1

	Hypermethylated

n	3925

CpG island location	CpG islands

Genomic location	TSS, 1st exon

Associated genes	1832

GO function terms	36

GO process terms	265

Canonical pathways (IPA)	19

Transcription factors	24

Hypomethylated

4615

Non-CGI

Gene body, outside genes

2057

27

53

3

1


	DNA binding consensus sequence	Putative binding site found in putative ATRX promoter	Biological roles	References

5'UTR of ATRX (+215 to +1)

YY1(+38 to +29)	SNCCATNTT	CGCCATTTT	Activator/repressor involved in neural development with roles in the testis and meiosis	[35,36]

ATRX promoter region

Inr element(-2 to +3)	CTTNACC	CTTAACC	Binds to basal transcription factor TFIID	[19]

CCAAT boxes(-2 to +3)(-38 to -34)(-69 to -65)	CCAAT	CCAAT	Binds NF-Y, C/EBP, GATA1, NF-E3	[42]

E2F(-6 to -1)	TTTGGCGC	ATTGGCGC	Family of TFs that regulate mitosis, apoptosis, DNA repair, development and differentiation	[52]

CREB(-122 to -117)	TGACGTCA	CGACGTCA	Mediation of basal and PKA-inducible transcription	[65]

HNF4(-173 to -168)	TGACCT	TGACCT	Liver factor involved in liver development and digestive function	[66]

CR1

STAT5B(-963 to -956)	TTCN3GAA	TTCAAGAA	Involved in immune response, erythropoesis and mammary development	[67]

CP2(-1017 to -1003)	A/TCTGG-CNRGN6CNRS	CTATT-CCAGN6GCAG	Regulates transcription of SRY. Initially shown to bind murine alpha-globin gene	[50]

E2F (-796 to -791)	TTTGGCGC	TTTGGCTG	See E2F above	[52]

CR2

HNF6(-1413 to -1408)	GAATCA	GAAGCY	Liver factor involved in regulation of HNF4 and pancreatic precursor cells	[68]

CR3

FOXJ2/NKX2-5(-12720 to -12714)	TNAAGTG	TTAAGTA	Involved in regulation of cardiogenesis	[69]

	DNA binding consensus sequence	Putative binding site found in putative ATRX promoter	Biological roles	References

5'UTR of ATRX (+215 to +1)

YY1(+38 to +29)	SNCCATNTT	CGCCATTTT	Activator/repressor involved in neural development with roles in the testis and meiosis	[35,36]

ATRX promoter region

Inr element(-2 to +3)	CTTNACC	CTTAACC	Binds to basal transcription factor TFIID	[19]

CCAAT 	CCAA		B

boxes(-2 to +3)(-38 to -34)(-69 to -65)	T	CCAAT	inds NF-Y, C/EBP, GATA1, NF-E3	[42]

E2F(-6 to -1)	TTTGGCGC	ATTGGCGC	Family of TFs that regulate mitosis, apoptosis, DNA repair, development and differentiation	[52]

CREB(-122 to -117)	TGACGTCA	CGACGTCA	Mediation of basal and PKA-inducible transcription	[65]

HNF4(-173 to -168)	TGACCT	TGACCT	Liver factor involved in liver development and digestive function	[66]

CR1

STAT5B(-963 to -956)	TTCN3GAA	TTCAAGAA	Involved in immune response, erythropoesis and mammary development	[67]

CP2(-1017 to -1003)	A/TCTGG-CNRGN6CNRS	CTATT-CCAGN6GCAG	Regulates transcription of SRY. Initially shown to bind murine alpha-globin gene	[50]

E2F (-796 to -791)	TTTGGCGC	TTTGGCTG	See E2F above	[52]

CR2

HNF6(-1413 to -1408)	GAATCA	GAAGCY	Liver factor involved in regulation of HNF4 and pancreatic precursor cells	[68]

CR3

FOXJ2/NKX2-5(-12720 to -12714)	TNAAGTG	TTAAGTA	Involved in regulation of cardiogenesis	[69]


Titer of serum from one sheep infected intrapulmonarily with 300.000 TCID 50 of virus K796	Virus strains

K796	10B	7W

Serum 13 months after infection with K796	128	16	8

Serum 3 years after infection with K796	256	32	16

Titer of serum from one naturally infected sheep in Cyprus	16	128	128

Titer of serum from one sheep infected intrapulmonarily with 300.000 TCID 50 of virus K796	K796	10B	7W

Serum 13 months after infection with K796	128	16	8

Serum 3 years after infection with K796	256	32	16

Titer of serum from one naturally infected sheep in Cyprus	16	128	128


Gene ID	Gene Product Description	Hilltop	Valley bottom

PF3D7_1121600	circumsporozoite-related antigen (CRA)	0.12 (0.05 - 0.19)	0.51 (0.39 - 0.63)

PF3D7_1035700	duffy binding-like merozoite surface protein (DBLMSP)	0.11 (0.05 - 0.17)	0.92 (0.33 - 1.51)

PF3D7_0108700	secreted ookinete protein, putative (PSOP24)	0.13 (0.01 - 0.25)	0.93 (0.41 - 1.44)

PF3D7_0206900.1	merozoite surface protein 5 (MSP5)	0.08 (0.05 - 0.11)	0.51 (0.26 - 0.76)


Traits/Disease	No. of Putative Associations

Conduct disorder (case status) *	11

Ischemic stroke	11

Atrial fibrillation/atrial flutter*	10

Permanent tooth development*	10

Conduct disorder (symptom count)*	9

Primary tooth development (time to first tooth eruption)*	8

Cleft lip*	7

Primary tooth development (number of teeth)*	5

Alcoholism (alcohol dependence factor score)*	4

Plasma coagulation factors*	3

Vitamin D insufficiency*	3

Vitamin D levels*	2

Atrial fibrillation*	1

Nonsyndromic cleft lip with or without cleft palate*	1

Plasma levels of Protein C*	1

Total	86

Traits/Disease	No. of Putative Associations

Permanent tooth development*	10

Conduct disorder (symptom count)*	9

Primary tooth development (time to first tooth eruption)*	8

Cleft lip*	7

Primary tooth development (number of teeth)*	5

Alcoholism (alcohol dependence factor score)*	4

Plasma coagulation factors*	3

Vitamin D insufficiency*	3

Vitamin D levels*	2

Atrial fibrillation*	1

Nonsyndromic cleft lip with or without cleft palate*	1

Plasma levels of Protein C*	1

Total	86


Sentence duration	N	Plaque index

Mean

Till 1 year	68	1.56

1–5 years	26	1.23

Over 5 years	6	1.00

Total	100	1.44

Kruskal–Wallis test	P < 0.05


HbB Genotype	Numbers (87)a	G6PD Genotype	Numbers (84)a	68 Status	126 Status	Deduced Phenotypeb

		68–126

AA	75 (86%)	VV-NNc	51 (61%)	Wildtype	Wildtype	G6PD B

SS	0	VV-DDd	8 (10%)	Wildtype	Mutant	G6PD A

AS	12 (14%)	M-De	6 (7%)	Mutant	Mutant	G6PD A-

AC	0	VM-ND	10 (12%)	Single Mutant	Single Mutant	G6PD A

CC	0	VV-ND	8 (9%)	Wildtype	Single Mutant	G6PD A

SC	0	VM-DD	1 (1%)	Single Mutant	Mutant	G6PD A

No PCR-product	3	No PCR-product	6


	Rape NOS	Gang Rape	Sexual Slavery	Combined Gang Rape and Sexual Slavery

	Number	Percent	Number	Percent	Number	Percent	Number	Percent

Physical:

 Pelvic pain	53	24.2	139	23.0	3	6.0	25	21.0

 Lumbar pain	24	11.0	72	11.9	0	0	16	13.4

 Abdominal pain	22	10.0	41	6.8	1	2.0	6	5.0

 Pregnancy	12	5.5	13	2.1	20	40.0	17	14.3

 Malaise	10	4.6	44	7.3	1	2.0	6	5.0

 Vaginal discharge	10	4.6	36	6.0	1	2.0	8	6.7

 Vaginal itching	9	4.1	25	4.1	1	2.0	8	6.7

 Abnormal menses	10	4.6	26	4.3	1	2.0	6	5.0

 Generally unwell	5	2.3	24	4.0	0	0	5	4.2

Social:

 Loss of possessions	55	25.1	147	24.3	10	20.0	19	16.0

 Loss of child/spouse	13	5.9	75	12.4	2	4.0	21	17.6

 Spousal abandonment	6	2.7	43	7.1	3	6.0	10	8.4

 Loss of other family	2	0.91	15	2.5	0	0	9	7.6

 Loss of home	1	0.46	9	1.5	0	0	1	0.84

Psychological:

 Anxiety about rape	53	24.2	154	25.5	18	36	31	26.1

 Anxiety about spousal abandonment	6	2.7	38	6.3	4	8	9	7.6

 Concern about STIs	25	11.4	76	12.6	4	8	19	16.0

 Concern about HIV	14	6.4	56	9.3	4	8	13	10.9

 General health concerns	16	7.3	66	10.9	7	14	9	7.6

 Grief about loss of spouse	9	4.1	40	6.6	1	2	10	8.4

 Grief about loss of child/children	8	3.7	25	4.1	0	0	3	2.5

	Rape NOS	Gang Rape	Sexual Slavery	Combined Gang Rape and Sexual Slavery

	Number	Percent	Number	Percent	Number	Percent	Number	Percent

Physical:

Pelvic pain	53	24.2	139	23.0	3	6.0	25	21.0

Lumbar pain	24	11.0	72	11.9	0	0	16	13.4

Abdominal pain	22	10.0	41	6.8	1	2.0	6	5.0

Pregnancy	12	5.5	13	2.1	20	40.0	17	14.3

Malaise	10	4.6	44	7.3	1	2.0	6	5.0

Vaginal discharge	10	4.6	36	6.0	1	2.0	8	6.7

Vaginal itching	9	4.1	25	4.1	1	2.0	8	6.7

Abnormal menses	10	4.6	26	4.3	1	2.0	6	5.0

Generally unwell	5	2.3	24	4.0	0	0	5	4.2

Social:

Loss of possessions	55	25.1	147	24.3	10	20.0	19	16.0

Loss of child/spouse	13	5.9	75	12.4	2	4.0	21	17.6

Spousal abandonment	6	2.7	43	7.1	3	6.0	10	8.4

Loss of other family	2	0.91	15	2.5	0	0	9	7.6

Loss of home	1	0.46	9	1.5	0	0	1	0.84

Psychological:

Anxiety about rape	53	24.2	154	25.5	18	36	31	26.1

Anxiety about spousal abandonment	6	2.7	38	6.3	4	8	9	7.6

Concern about STIs	25	11.4	76	12.6	4	8	19	16.0

Concern about HIV	14	6.4	56	9.3	4	8	13	10.9

General health conc	1	7.	66					7.6

erns	6	3		10.9	7	14	9

Grief about loss of spouse	9	4.1	40	6.6	1	2	10	8.4

Grief about loss of child/children	8	3.7	25	4.1	0	0	3	2.5


	Key inclusion and exclusion criteria	Orchard et al. [7]	Meisser et al. [8]	Noehren et al. [11]	Ferber et al. [12]	Phinyonmark et al. [20]	Foch et al. [21]	Foch and Milner [22]	Foch and Milner [23]	Grau et al. [24]	Hein et al. [25]	Miller et al. [26]a	Miller et al. [27]a	Noehren et al. [28]

1	Clear definition of location of pain was reported	✓	✓	X	✓	✓	✓	X	X	✓	✓	X	X	✓

2	Reports a typical history of ITBS with symptoms consistent to the condition	✓	X	X	✓	✓	✓	X	X	✓	✓	X	✓	✓

4	Diagnosis was confirmed by a medical practitioner/physiotherapist/ trainer	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓

4	A positive clinical test (Obers/Nobles)/ palpation	✓	✓	X	X	✓	X	X	X	✓	✓	X	✓	✓

5	No previous knee surgery	✓	X	✓	✓	✓	X	✓	✓	✓	✓	✓	X	✓

6	No internal derangement or other sources of lateral knee pain present	✓	✓	✓	✓	✓	X	✓	✓	✓	✓	✓	X	✓

7	No previous spine or lower limb injury	✓	✓	✓	✓	✓	X	X	✓	✓	✓	✓	X	✓

Criteria’s Met	7	5	4	6	7	3	3	4	7	7	4	3	7

	Key inclusion and exclusion criteria	Orchard et al. [7]	Meisser et al. [8]	Noehren et al. [11]

1	Clear definition of location of pain was reported	✓	✓	X

2	Reports a typical history of ITBS with symptoms consistent to the condition	✓	X	X

4	Diagnosis was confirmed by a medical practitioner/physiotherapist/ trainer	✓	✓	✓

4	A positive clinical test (Obers/Nobles)/ palpation	✓	✓	X

5	No previous knee surgery	✓	X	✓

6	No internal derangement or other sources of lateral knee pain present	✓	✓	✓

7	No previous spine or lower limb injury	✓	✓	✓

Criteria’s Met	7	5	4

Ferber et al. [12]	Phinyonmark et al. [20]	Foch et al. [21]	Foch and Milner [22]	Foch and Milner [23]	Grau et al. [24]	Hein et al. [25]	Miller et al. [26]a	Miller et al. [27]a	Noehren et al. [28]

✓	✓	✓	X	X	✓	✓	X	X	✓

✓	✓	✓	X	X	✓	✓	X	✓	✓

✓	✓	✓	✓	✓	✓	✓	✓	✓	✓

X	✓	X	X	X	✓	✓	X	✓	✓

✓	✓	X	✓	✓	✓	✓	✓	X	✓

✓	✓	X	✓	✓	✓	✓	✓	X	✓

✓	✓	X	X	✓	✓	✓	✓	X	✓

6	7	3	3	4	7	7	4	3	7


	Ordinary light	Infrared ray light

ICG-positive nodedetection	28/36(78 %)	36/36

The number ofICG-positive nodes	3.4 ± 3.7*(0 to 16)+	9.2 ± 5.9*(2 to 25)+

Lymph nodemetastasis sensitivity	1/5(20 %)	5/5(100 %)

	Ordinary light

ICG-positive nodedetection	28/36(78 %)

The number ofICG-positive nodes	3.4 ± 3.7*(0 to 16)+

Lymph nodemetastasis sensitivity	1/5(20 %)


Test 	Day 0 (admission)	Day 13 (discharge)

Coxsackie A9 (NT)	8 Units	16 Units

Coxsackie B1 (NT)	16 Units	32 Units

Coxsackie B2 (NT)	<4 Units	<4 Units

Coxsackie B3 (NT)	32 Units	64 Units

Coxsackie B4 (NT)	<4 Units	<4 Units

Coxsackie B5 (NT)	<4 Units	<4 Units

Coxsackie B6 (NT)	<4 Units	<4 Units

Test	Day 0 (admission)	Day 13 (discharge)

Coxsackie A9 (NT)	8 Units	16 Units

Coxsackie	16 Un	32 Uni

Test	Day 0 (admission)	Day 13 (discharge)

 B1 (NT)	its	ts

Coxsackie B2 (NT)	<4 Units	<4 Units

Coxsackie B3 (NT)	32 Units	64 Units

Coxsackie B4 (NT)	<4 Units	<4 Units

Coxsackie B5 (NT)	<4 Units	<4 Units

Coxsackie B6 (NT)	<4 Units	<4 Units


Who Would Use the App?	When Would They Use the App?	How Useful Is an App?	What Should Be in the App?	Who or How Should It Be Advertised to Users?

Parents of children ages 0–6First time momsParents about to switch their child to a new seatCaregiversFamilyBabysittersDads say they are less likely to use it but moms say dads would use it a lot	Before the baby is bornWhen buying a new seat (process) or about to switch seatsExternal caregiver installingFirst time installation with new seatWhen looking for car seat check pointsTroubleshootingIn need of non-installation factoids/frequently asked questions (expiration dates) 	AdvantagesOn the go informationSimple to useAccessibleProvides direct infoEasier to readVisual assistanceDisadvantagesSome preferred websiteApps may be difficult to navigateUnfamiliarity with appsNot useful when installing—“keep checking your phone”	Car seat check locator and appointment schedulerWhat seat fit best in the carHow to install in different types of carsConsumer product reviewsCar seat laws and policiesTypes of car seats for height, weight, and ageFAQ’s, safety myths vs. factsExpiration datesTravelingOnline forum (social tools)Search functionMultiple languagesSpanishVideos and imagesTroubleshooting info and tools—inch and pinch test	Who:Not manufacturersDoctors in officeCHOPInsurance companiesSafekids WorldwideHow:No brochuresParent magazinesWebsite of CRS companiesPoster in waiting roomPrenatal and parenting classes

Who Would Use the App?	When Would They Use the App?

Parents of children ages 0–6First time momsParents about to switch their child to a new seatCaregiversFamilyBabysittersDads say they are less likely to use it but moms say dads would use it a lot	Before the baby is bornWhen buying a new seat (process) or about to switch seatsExternal caregiver installingFirst time installation with new seatWhen looking for car seat check pointsTroubleshootingIn need of non-installation factoids/frequently asked questions (expiration dates)

How Useful Is an App?	What Should Be in the App?	Who or How Should It Be Advertised to Users?

AdvantagesOn the go informationSimple to useAccessibleProvides direct infoEasier to readVisual assistanceDisadvantagesSome preferred websiteApps may be difficult to navigateUnfamiliarity with appsNot useful when installing—“keep checking your phone”	Car seat check locator and appointment schedulerWhat seat fit best in the carHow to install in different types of carsConsumer product reviewsCar seat laws and policiesTypes of car seats for height, weight, and ageFAQ’s, safety myths vs. factsExpiration datesTravelingOnline forum (social tools)Search functionMultiple languagesSpanishVideos and imagesTroubleshooting info and tools—inch and pinch test	Who:Not manufacturersDoctors in officeCHOPInsurance companiesSafekids WorldwideHow:No brochuresParent magazinesWebsite of CRS companiesPoster in waiting roomPrenatal and parenting classes


Organizational	Socio-cultural	Intrinsic

Motivators

• Opportunities for higher qualifications	• Respect	• Serving people

• Good working and hygienic conditions	• Social rewards	• Work interest

• Personal safety		• Career growth

• Good professional experience		• Ability to support oneself and family

• Good pay		• Autonomy

• Financial incentives other than pay		• Empowerment

Demotivators

• Less pay	• Disrespect	• Less career growth

• Poor working and hygienic conditions	• Poor interpersonal relations	• Inability to support oneself and family

• Fewer opportunities for higher qualifications	• Less social rewards

• Less personal safety	• Less personal and social time

• Heavy work load

• Long duty hours

• Resource unavailability

• Fewer promotion opportunities

• Poor supervision

Organizational	Socio-cultural	Intrinsic

• Fewer opportunities for higher qualifications	• Less social rewards

• Less personal safety	• Less personal and social time

• Heavy work load

• Long duty hours

• Resource unavailability

• Fewer promotion opportunities

• Poor supervision


Cost variable	Source	Unit cost in public system (Dollar)	Unit cost in private system (Dollar)

Medical visit

Public	Hospital accounts department/DMA	5*	125 (range 100-150)

Medication

Pain killer	Central Medical Store	0.05/500 mgx2×3=0.30**	2.00

ORS	Central Medical Store	0.75/packx3=2.25	4.5×3=13.5

Antibiotics	Central Medical Store	0.03/250 mgx3×3×5=1.35***	8.00

Gravol	Central Medical Store	0.05/50 mgx4×2=0.4****	2.00

Loperamide	Private dispensary	0.50/2 mgx2=1.0*****	2.00

IV fluid (0.9% sodium solution)	Central Medical Store	3.42/litre

Testing of stool specimens	Billing department, PMH	20.00

Loss of working days

Caregiver service	Labour standard order (Minimum wage)	28.75/day

Duration of illness	Population survey	2 days (Median value)

Cost variable

Medical visit

Public

Medication

Pain killer

ORS

Antibiotics

Gravol

Loperamide

IV fluid (0.9% sodium solution)

Testing of stool specimens

Loss of working days

Caregiver service

Duration of illness

Source	Unit cost in public system (Dollar)	Unit cost in private system (Dollar)

Hospital accounts department/DMA	5*	125 (range 100-150)

Central Medical Store	0.05/500 mgx2×3=0.30**	2.00

Central Medical Store	0.75/packx3=2.25	4.5×3=13.5

Central Medical Store	0.03/250 mgx3×3×5=1.35***	8.00

Central Medical Store	0.05/50 mgx4×2=0.4****	2.00

Private dispensary	0.50/2 mgx2=1.0*****	2.00

Central Medical Store	3.42/litre

Billing department, PMH	20.00

Labour standard order (Minimum wage)	28.75/day

Population survey	2 days (Median value)


Neuroprotectant	n (%*)

Edaravone	95 (8.4)

Ganglioside GM1	29 (2.6)

Cattle encephalon glycoside and ignotin	112 (9.9)

Cinepazide	56 (5.0)

Citicholine	334 (29.6)

Other†	198 (17.5)

Unspecified	321 (28.4)


Self-rated spiritual health	Ideators (%)	Non-ideators (%)	χ2	p-Value

Excellent OR good	117 (49.37)	2713 (85.10)	196.23	<.0001

Fair OR poor OR uncertain	120 (50.63)	475 (14.90)

-rated spiritual health	eators (%)	tors (%)	2	p-Value

Excellent OR good	117 (49.37)	2713 (85.10)	196.23	<.0001

Fair OR poor OR uncertain	120 (50.63)	475 (14.90)


Variable	Controls (n = 73)	Participants (n = 73)	p valuea

Lipoprotein subclassb

VLDL and chylomicron particle concentrations (nmol/L)

 Total VLDL and chylomicron particles	82.0 ± 45.3	87.5 ± 39.6	0.15

 Large VLDL and chylomicron particles	4.6 ± 6.3	8.2 ± 6.8	< 0.01c

 Medium VLDL particles	38.1 ± 28.5	39.7 ± 25.7	0.50c

 Small VLDL particles	39.3 ± 19.9	39.7 ± 17.2	0.90

LDL particle concentrations (nmol/L)

 Total LDL particles	1253 ± 367	1437 ± 477	0.01

 Large LDL particles	337 ± 211	251 ± 218	< 0.01c

 Intermediate LDL particles	45.8 ± 38.5	72.6 ± 50.2	< 0.01c

 Small LDL particles	870 ± 434	1113 ± 478	< 0.01

HDL particle concentrations (μmol/L)

 Total HDL particles	34.7 ± 6.7	32.1 ± 5.6	0.01

 Large HDL particles	6.4 ± 3.5	4.6 ± 3.4	< 0.01

 Medium HDL particles	5.2 ± 4.9	5.9 ± 4.8	0.25c

 Small HDL particles	23.1 ± 7.0	21.7 ± 5.8	0.17

Mean particle sizes (nm)

 VLDL size	50.6 ± 9.0	55.6 ± 10.4	< 0.01

 LDL size	20.7 ± 0.9	20.2 ± 0.8	< 0.01

 HDL size	8.9 ± 0.4	8.6 ± 0.3	< 0.01

Physiological variablesd

 Age	60.0 ± 7.8	60.3 ± 8.0	0.79

 Body mass index (kg/m2)	28.2 ± 3.7	34.0 ± 7.0	< 0.01

 Systolic blood pressure (mm Hg)	133 ± 17	136 ± 17	0.12c

 Diastolic blood pressure (mm Hg)	78.9 ± 9.2	80.8 ± 9.8	0.50c

 HDL-cholesterol (mg/dl)	50.5 ± 13.7	43.7 ± 13.1	< 0.01c

 LDL-cholesterol (mg/dl)	111 ± 33	111 ± 39	0.64c

 Total cholesterol (mg/dl)	191 ± 42	193 ± 47	0.82

 Triglycerides (mg/dl)	148 ± 100	189 ± 99	< 0.01

 Physical fitness (Bruce score)	10.4 ± 2.8	6.6 ± 2.2	< 0.01

 Framingham risk (× 100)	7.4 ± 6.8	10.7 ± 8.5	0.02c

Variable	Controls (n = 73)

Lipoprotein subclassb

VLDL and chylomicron particle concentrations (nmol/L)

Total VLDL and chylomicron particles	82.0 ± 45.3

Large VLDL and chylomicron particles	4.6 ± 6.3

Medium VLDL particles	38.1 ± 28.5

Small VLDL particles	39.3 ± 19.9

LDL particle concentrations (nmol/L)

Total LDL particles	1253 ± 367

Large LDL particles	337 ± 211

Intermediate LDL particles	45.8 ± 38.5

Small LDL particles	870 ± 434

HDL particle concentrations (μmol/L)

Total HDL particles	34.7 ± 6.7

Large HDL particles	6.4 ± 3.5

Medium HDL particles	5.2 ± 4.9

Small HDL particles	23.1 ± 7.0

Mean particle sizes (nm)

VLDL size	50.6 ± 9.0

LDL size	20.7 ± 0.9

HDL size	8.9 ± 0.4

Physiological variablesd

Age	60.0 ± 7.8

Body mass index (kg/m2)	28.2 ± 3.7

Systolic blood pressure (mm Hg)	133 ± 17

Diastolic blood pressure (mm Hg)	78.9 ± 9.2

HDL-cholesterol (mg/dl)	50.5 ± 13.7

LDL-cholesterol (mg/dl)	111 ± 33

Total cholesterol (mg/dl)	191 ± 42

Triglycerides (mg/dl)	148 ± 100

Physical fitness (Bruce score)	10.4 ± 2.8

Framingham risk (× 100)	7.4 ± 6.8


	Regular expression method		Term voting method

TOTAL terms	98435	100%	98435	100%

Selected set	13755	14%	13755	14%

Excluded set	84680	86%	84680	86%

Sample of excluded	3140	100%

Wrong (false negative)	49	1.6%

Correct (true negative)	3091	98.4%

Proportionate number of bona fide terms in excluded set	1321

Sample of included	2070	100%	2287	100%

Wrong (false positive)	1538	74.3%	1974	86.3%

Correct (true positive)	532	25.7%	313	13.7%

Probable number of bona fide terms in selected set	3535		1883

Recall	0.728

Precision	0.257		0.137

	Regular expression method

TOTAL terms	98435	100%

Selected set	13755	14%

Excluded set	84680	86%

Sample of excluded	3140	100%

Wrong (false negative)	49	1.6%

Correct (true negative)	3091	98.4%

Proportionate number of bona fide terms in excluded set	1321

Sample of included	2070	100%

Wrong (false positive)	1538	74.3%

Correct (true positive)	532	25.7%

Probable number of bona fide terms in selected set	3535

Recall	0.728

Precision	0.257


Target gene	Forward primer (5′ to 3′)	Reverse primer (5′ to 3′)	Source

Mad2	GAGTTCTTCTCATTCGGCATCA	CCAATCTTTCAGTTGTTCCACC	PrimerBank

Bub1	TGCTGCACAACTTGCGTCTAC	TCAACGCCCAACTCTGCCT	PrimerBank

APC	CCAACAAGGCTACGCTATGC	ATCTGCTCGCCAAGACAAAT	PrimerBank

β-actin	ATCATGTTTGAGACCTTCAACA	CATCTCTTGCTCGAAGTCCA	PrimerBank


Comparison	BC1 vs BC2

Successful Calls for Both	SNPs	134128046

	%	99.241

Concordant Calls (All)	SNPs	134109060

	%	99.986

Concordant Calls (Hom)	SNPs	98050788

	%	99.989

Concordant Calls (Het)	SNPs	36058272

	%	99.977


Inner cortical width of thoracic pedicles (mm)	No. of thoracic pedicles instrumented	No. of thoracic pedicles accurately instrumented	Accuracy (%)

0–1.0	194	68	35.05

1.1–2.0	176	115	65.34

2.1–3.0	352	304	86.36

≥3.1	376	339	90.16

Total	1098	826	75.23

Inner cortical width of thoracic pedicles (mm)	No. of thoracic pedicles instrumented	No. of thoracic pedicles accurately instrumented

0–1.0	194	68

1.1–2.0	176	115

2.1–3.0	352	304

≥3.1	376	339

Total	1098	826


EDA-Q items (18 items)	Corresponding DISCO items (17 items)	DISCO variables

Obsessively resists and avoids ordinary demands	Lack of co-operation	LACKCOP

Has difficulty complying unless carefully presented

Is driven by the need to be in charge	Using age peers as mechanical aids, bossy and domineering	CPEERAD*

Tells other children how to behave

Finds everyday pressures intolerably stressful	Anxiety	ANXIETY

Mimics adult mannerisms and styles	Repetitive acting out roles	CTROL*

Shows little shame or embarrassment	Behaviour in public places	BEHAPUB

Embarrassing remarks in public	REMARK

Good at getting around others	Apparently manipulative behaviour	MANBEH*

Unaware of differences between self and authority figures	Awareness of own identity	CIDENT*

Attempts to negotiate better terms with adults

If pressurised to do things, may have a ‘meltdown’	Temper tantrums	TEMPER

Mood changes rapidly	Changeable mood	MOODCH

Knows what to do or say to upset specific people	Difficulties with other people	DIFPEOP

Blames or targets a particular person	Harassment of others	HARAS*

Blaming other people	BLAME*

Denies behaviour, even when caught red-handed	Fantasising, lying, cheating, stealing	LYING*

Outrageous behaviour to get out of doing something	Socially shocking behaviour	SHOCK*

Extreme emotional responses to small events	Inappropriate sociability (rapid, inexplicable changes from loving to aggression)	CINAPP*

Social interaction has to be on his/her own terms	One-sided social approaches	CONESID


 	SA-test (reaction time (msec)

Active diet	Control diet

time 0	1320 ± 20	1320 ± 21

45 min	1219 ± 19	1230 ± 21

120 min	1182 ± 21	1202 ± 23


	Treatment-naïve cancer patients (n= 555)

Age, years (IQR)	62 (52-71)

Male gender, n (%)	227 (41%)

BMI kg/m2, (IQR)	25.0 (22.6–28.4)

Comorbidities

 Known CAD, n (%)	28 (5%)

 Heart Failure, n (%)	38 (7%)

 Diabetes mellitus, n (%)	43 (8%)

 Arterial Hypertension, n (%)	250 (45%)

 CKD, n (%)	31 (6%)

 COPD, n (%)	113 (20%)

Cancer disease stage*

 Stage 1, n (%)	96 (17%)

 Stage 2, n (%)	50 (9%)

 Stage 3, n (%)	108 (19%)

 Stage 4, n (%)	183 (33%)

Hepatic involvement

 Primary hepatic, biliary tract or pancreatic malignoma, n (%)	27 (5%)

 Hepatic metastases, n (%)	51 (10%)

Laboratory parameters

 GFR, mL/min/1.73 m2 (IQR)	74.5 (63.7–86.0)

 BUN, mg/dl (IQR)	15 (12-19)

 BChE, kU/l (IQR)	7.31 (6.10–8.40)

 AST (GOT), U/l (IQR)	24 (19–31)

 ALT (GPT), U/l (IQR)	22 (16–32)

 GGT, U/l (IQR)	32 (21–63)

 Bilirubin, mg/dl (IQR)	0.58 (0.44-0.79)

 Albumin, g/l (IQR)	43.0 (40.0–45.4)

 CRP, mg/dl (IQR)	0 (0-1)

 SAA, μg/ml (IQR)	8 (4-26)

 IL-6, pg/ml (IQR)	2 (2–3)


Time points of measurements	IOP	ONSD

T0	Patient awake in supine position before induction of anaesthesia	X	-

T1	20 min after induction of general anaesthesia in supine position	X	X

T2	After insufflation of the abdomen with CO2 in supine position	X	X

T3	After 30 min in 45° Trendelenburg position with the abdomen still insufflated with CO2	X	X

T4	Control of Santorini’s plexus in 45° Trendelenburg position with CO2 still insufflated	X	X

T5	Anaesthetised before awakening in supine position	X	X

Time points of measurements	IOP	ONSD

T0	Patient awake in supine position before induction of anaesthesia	X	-

T1	20 min after induction of general anaesthesia in supine position	X	X

T2	After insufflation of the abdomen with CO2 in supine position	X	X

T	After 30 min in 45°

Time points of measurements	IOP	ONSD

3	Trendelenburg position with the abdomen still insufflated with CO2	X	X

T4	Control of Santorini’s plexus in 45° Trendelenburg position with CO2 still insufflated	X	X

T5	Anaesthetised before awakening in supine position	X	X


Proteins present in all 8 Mimiviridae genomes

CLS10031	A1L transcription factor VLTF-2	CLS10052	Proliferating cell nuclear antigen

CLS10071	A2L transcription factor VLTF-3	CLS10035	protein disulfide Isomerase/thioredoxin family

CLS10199	asnB, asparagine synthetase B	CLS10216	putative DNA-directed RNA polymerase II subunit N

CLS10039	capsid protein	CLS10047	replication factor C small subunit

CLS10262	D5-like helicase-primase	CLS10049	replication factor C small subunit

CLS10015	DEAD/SNF2-like helicase or ATP-dependent RNA helicase	CLS10258	ribonuclease H

CLS10089	DNA directed RNA polymerase subunit L	CLS10041	ribonuclease III

CLS10259	DNA mismatch repair ATPase MutS	CLS10130	ribonucleosidediphosphatereductase large subunit

CLS10104	DNA polymerase elongation subunit family B	CLS10252	ribonucleosidediphosphatereductase small subunit

CLS10201	DNA topoisomerase IB	CLS10028	TATA-box-binding protein

CLS10230	DNA topoisomerase II	CLS10057	Transcription factor S-II (TFIIS)-domain-containing protein

CLS10090	DNA-dependent RNA polymerase subunit Rpb9/M	CLS10055	transcription initiation factor IIB

CLS10250	DNA-directed RNA polymerase subunit 5 (RPB5)	CLS10011	ubiquitin-conjugating enzyme E2

CLS10261	DNA-directed RNA polymerase subunit 6	CLS10214	Ulp1-like protease

CLS10076	DNA-directed RNA polymerase subunit alpha	CLS10066	VV A18-like helicase

CLS10053	DNA-directed RNA polymerase subunit beta	CLS10068	VV A32 virion packaging ATPase

CLS10249	DNA-directed RNA polymerase subunit E’ (RPB7)	CLS10218	YqaJ-like viral recombinase

CLS10024	Erv1 / Alr family oxidoreductase	CLS10212	hypothetical protein

CLS10221	eukaryotic translation initiation factor 4E-like protein	CLS10222	hypothetical protein

CLS10086	FtsJ-like methyltransferase	CLS10233	hypothetical protein

CLS10030	Holliday junction resolvase	CLS10236	hypothetical protein

CLS10056	metallopeptidase WLM	CLS10032	hypothetical protein

CLS10219	mRNA capping enzyme	CLS10043	hypothetical protein

CLS10088	NUDIX hydrolase	CLS10046	hypothetical protein

CLS10224	poxvirus poly(A) polymerase catalytic subunit-like protein	CLS10070	hypothetical protein

CLS10253	probable ubiquitin carboxyl-terminal hydrolase	CLS10081	hypothetical protein

Genes missing in one or two OLPG genomes but present in all the other Mimiviridae genomes

CLS10059	AAA family ATPase	CLS10009	Lon domain protease

CLS10021	chaperone protein DnaJ	CLS10033	patatin-like phospholipase

CLS10022	chaperone protein DnaJ	CLS10072	Prolyl 4-hydroxylase

CLS10082	heat shock 70 kDa protein	CLS10091	thymidylate synthase

CLS10042	hypothetical protein	CLS10010	XRN 5'-3' exonuclease


	MMSE Non-demented	MMSE Demented	EMSE Non-demented	EMSE Demented

Below 5th pcntle (MMSE cut-point = 21, EMSE cut-point = 41)	618 (3%)	622 (73%)	810 (5%)	474 (77%)

Below 10th pcntle (MMSE cut-point = 23, EMSE cut-point = 45)	1443 (8%)	707 (84%)	1676 (10%)	524 (88%)

Below -1 SD (MMSE cut-point = 23.1, EMSE cut-point = 44.5)	2075 (13%)	739 (90%)	1676 (10%)	524 (88%)

Below -2 SD (MMSE cut-point = 12.9, EMSE cut-point-24.5)	5 (0%)	229 (24%)	36 (0%)	125 (19%)


Trial centre	Trial arm

Bristol	Control (%)

	IPB+ (%)

	IPB only (%)

	Total (%)

Newcastle	Control (%)

	IPB+ (%)

	IPB only (%)

	Total (%)

Norwich	Control (%)

	IPB+ (%)

	IPB only (%)

	Total (%)

Nottingham	Control (%)

	IPB+ (%)

	IPB only (%)

	Total (%)

Total by questionnaire type (%)


 	Subchondral bone volume	Subchondral bone migration area

 	Pearson's r	P value	Pearson's r	P value

Weeks	0.799	<0.001	0.799	<0.001

Gross appearance	0.865	0.001	0.923	<0.001

Histology	0.649	0.059	0.520	0.152

	Subchondral bone volume	Subchondral bone migration area

	Pearson's r	P value	Pearson's r	P value

Histology	0.649	0.059	0.520	0.152


Country	Study type	Phase	n	Primary objective	Major findings

Thailand	HNV, PK and tolerability	1	24	PK and bio-availability of AS and MQ; administered separately and as a coformulation to healthy volunteers and patients	No difference was seen in the bio-equivalence of MQ in the two formulations; although a difference was seen for AS/DHA, this was not concluded to be clinically relevant[20]

PK, efficacy and safety	2	50	Population PK model of new dosage regime of MQ with AS in loose combination over three days	Splitting the 25 mg/kg dose of MQ into three doses of 8 mg/kg improved oral bio-availability compared to the conventional split-dose regimen results. New regimen was well tolerated and with an equivalent therapeutic response[21]

PK, efficacy and safety	2b	50	Safety and PK of ASMQ FDC vs non-fixed AS+MQ against multi-drug resistant falciparum malaria in adults	FDC well-tolerated with broadly similar PK profiles to non-fixed AS plus MQ[22]. The observed slowing of heart rate was best explained by malaria resolution[23]

Efficacy and safety	3	500	ASMQ FDC with separate tablets in adults and children with uncomplicated multidrug-resistant falciparum malaria	Cure rates were 91.9% for the FDC after 63 days, with a lower incidence of vomiting compared to those in the loose tablets group[24]

Myanmar	Competitive Effectiveness	4	808	Effectiveness of five artemisinin combination regimens with or without PQ in uncomplicated falciparum malaria	ASMQ provided the greatest post-treatment suppression of malaria after 63 days, with the addition of PQ substantially reducing transmission potential of malaria[25]

India	Efficacy and safety	3	77	PCR corrected cure rate of ASMQ FDC in adult patients with uncomplicated falciparum malaria	Mean parasite clearance time of 48 hours

Brazil	Intervention study: PK Efficacy and safety	3b/4	23,845	Effectiveness of ASMQ FDC in reducing malaria transmission in the Juruá valley	Early detection of malaria and treatment with ASMQ FDC was feasible and efficacious, significantly reduced the incidence and morbidity of falciparum malaria[26]

Country	Study type	Phase	n	Primary objective	Major findings

Thailand	HNV, PK and tolerability	1	24	PK and bio-availability of AS and MQ; administered separately and as a coformulation to healthy volunteers and patients	No difference was seen in the bio-equivalence of MQ in the two formulations; although a difference was seen for AS/DHA, this was not concluded to be clinically relevant[20]

PK, efficacy and safety	2	50	Population PK model of new dosage regime of MQ with AS in loose combination over three days	Splitting the 25 mg/kg dose of MQ into three doses of 8 mg/kg improved oral bio-availability compared to the conventional split-dose regimen results. New regimen was well tolerated and with an equivalent therapeutic response[21]

PK, eff			Safety and PK of ASMQ FDC vs non-fixed AS+MQ against 	FDC well-tolerated with broadly s

Country	Study type	Phase	n	Primary objective	Major findings

	icacy and safety	2b	50	multi-drug resistant falciparum malaria in adults	imilar PK profiles to non-fixed AS plus MQ[22]. The observed slowing of heart rate was best explained by malaria resolution[23]

Efficacy and safety	3	500	ASMQ FDC with separate tablets in adults and children with uncomplicated multidrug-resistant falciparum malaria	Cure rates were 91.9% for the FDC after 63 days, with a lower incidence of vomiting compared to those in the loose tablets group[24]

Myanmar	Competitive Effectiveness	4	808	Effectiveness of five artemisinin combination regimens with or without PQ in uncomplicated falciparum malaria	ASMQ provided the greatest post-treatment suppression of malaria after 63 days, with the addition of PQ substantially reducing transmission potential of malaria[25]

India	Efficacy and safety	3	77	PCR corrected cure rate of ASMQ FDC in adult patients with uncomplicated falciparum malaria	Mean parasite clearance time of 48 hours

Brazil	Intervention study: PK Efficacy and safety	3b/4	23,845	Effectiveness of ASMQ FDC in reducing malaria transmission in the Juruá valley	Early detection of malaria and treatment with ASMQ FDC was feasible and efficacious, significantly reduced the incidence and morbidity of falciparum malaria[26]


Outcome and complication	No. (%)

Mortality	6 (14.2%)

30 day	2 (4.8%)

1 year	1 (2.4%)

5 years	2 (4.8%)

Complications

 Grade I	14 (33.3%)

 Grade II	2 (4.8%)

 Grade IIIa	4 (9.5%)

 Grade IIIb	2 (4.8%)

 Grade IV	3 (7.1%)

Massive intraoperative bleeding and edema.	2 (4.8%)

Wound infection	4 (9.5%)

New hemiparesis, sensory changes	4 (9.5%)

New cranial nerve palsy	7 (16.7%)

Deep vein thrombosis.	1 (2.4%)

Discharge location	42 (100%)

Home ± rehabilitation	24 (57.1%)

Rehabilitation center	14 (33.3%)

Convalescence hospital	2 (4.8%)

Hospital persist	2 (4.8%)

Karnofsky score at 1 year	(n = 38)

 > 70	23 (60.5%)

 < 70	15 (39.5%)

Karnofsky score at 5 years	(n = 34)

 > 70	20 (58.8%)

 < 70	14 (41.2%)


Ordered by socioeconomic variableb	Male	Female

Prevalencec	Times/dayd	Prevalencec	Times/dayd

Based on ranges. n = 24e

 Reason for extreme rates	1.06	1.26	1.26	6.00

 Difference of extreme rates	4.53	0.11	17.16	0.45

 Prevalence attributable to population	−3.44	−0.13	1.69	−0.07

 Prevalence attributable to population (%)	−4.39	−44.00	2.49	45.28

Based on disparity or dispersion. n = 33

 Pearcy-Keppel	0.57	2.29	0.66	1.23

 Pearcy-Keppel (Adjusted A)	28.02	0.21	25.34	0.08

 Variance between groups (VEG)	60.14	0.02	105.35	0.01

 Variance between groups (VEGA)	0.77	0.05	1.55	0.05

Based on disproportionality and concentration. n = 24

 Gini	0.05	0.22	0.08	0.25

 Concentration	0.01	0.12	−0.01	−0.05

Based on regression models. n = 24

 Coefficient β	0.12	−0.00	0.24	0.00

 Coefficient of determination	0.00	0.00	0.02	0.11

 Inequality of slope	3.23	0.22	−3.16	−0.05

 Inequality of Pamuk or relative	0.04	0.73	0.05	0.28

 Inequality of Kunst and Mackenbach	1.04	1.53	1.05	1.33

 Dimensional inequality	3.23	0.49	1.04	1.29

Based on the concept of entropy. n = 33

 Kullback-Liebler (Z)	0.01	0.09	0.01	0.11

 Hoover or dissimilitudes (Z)	0.04	0.15	0.06	0.17

 Theil (Z)	0.01	0.08	0.01	0.11


Pollutant	Concentration	Averaging period	Permitted exceedences each year

Cuprum [μ/m3]	0,6 μg/m3	1 year	n/a

PM10	40 μg/m3	1 year	n/a

Lead (Pb)	0,35 μg/m3	1 year	n/a

Pollutant	Concentration

Cuprum [μ/m3]	0,6 μg/m3

PM10	40 μg/m3

Lead (Pb)	0,35 μg/m3

Averaging period	Permitted exceedences each year

1 year	n/a

1 year	n/a

1 year	n/a


Publication	Zona pellucida breach	Embryonic stage	No of ET	Pregnancies conceived	Intervention	Outcome

ICSI	Assisted hatching	Embryo biopsy

Salat-Baroux et al., 1994	No	No	No	Cleavage	4	MCTA triplets	Reduction	DCDA miscarriage

DCDA twins

Belaisch-Allart et al., 1995	No	No	No	Cleavage	3	MCTA triplets	Nil	Delivery ?weeks

Yakin et al., 2001	Yes	No	No	Blastocyst	3	MCTA triplets	Reduction	DCDA delivery 36 weeks

DCDA twins

Ghulmiyyah et al., 2003	Yes	Yes	No	Blastocyst	2	MCTA triplets	Nil	CS at week 31

Ulug et al., 2004	Yes	Yes	No	Cleavage	3	MCTA triplets	Reduction	Singleton CS at week 38

Singleton

Yes	Yes	No	Cleavage	3	MCTA triplets	Nil	CS at week 34

Unger et al., 2004	Yes	No	No	Blastocyst	2	MCTA triplets	Reduction	Ongoing MCDA pregnancy 22 weeks

MCDA twins

Zikopoulos et al., 2004	Yes	No	No	Blastocyst	2	MCTA triplets	Reduction	Ongoing MCDA pregnancy 20 weeks

MCDA twins

Risquez et al., 2004	Yes	Yes	No	Cleavage	1	MCTA triplets	Nil	Ongoing pregnancy

16 weeks

Jain et al., 2004	No	No	No	Blastocyst	2	MCTA triplets	Nil	Ongoing pregnancy 7 weeks

Henne et al., 2005	No	No	No	Blastocyst	2	MCTA triplets	Termination

Yanaihara et al., 2007	No	No	No	Blastocyst	1	MCTA triplets	Termination

Lee et al., 2008	Yes	No	No	Blastocyst	1	MCTA triplets	Nil	CS at 33 weeks

Faraj et al., 2008	No	No	No	Blastocyst	1	MCTA triplets	Nil	CS at 32 weeks

Pantos et al., 2004	Yes	Yes	No	Day 4	3	MCTA triplets	Reduction	Singleton CS at 38 weeks

singleton

Haimov-Kochman et al., 2009	Yes	No	Yes	Day 4	3	MCTA triplets	Reduction	Singleton delivery at 38 weeks

singleton

Liu et al., 2010	No	No	No	Cleavage	2	MCQA	Nil	Miscarriage

Gurunath et al., 2015	No	No	No	Blastocyst	2	MCTA	Termination

Saravelos et al., 2015	Yes	No	Yes	Day 4	1	MCQA	Reduction	MCDA CS at 35 + 6 weeks

No	No	No	Blastocyst	1	MCTA	Reduction	Ongoing MCDA pregnancy

Publication

Salat-Baroux et al., 1994

Belaisch-Allart et al., 1995

Yakin et al., 2001

Ghulmiyyah et al., 2003

Ulug et al., 2004

Unger et al., 2004

Zikopoulos et al., 2004

Risquez et al., 2004

Jain et al., 2004

Henne et al., 2005

Yanaihara et al., 2007

Lee et al., 2008

Faraj et al., 2008

Pantos et al., 2004

Haimov-Kochman et al., 2009

Liu et al., 2010

Gurunath et al., 2015

Saravelos et al., 2015

Zona pellucida breach	Embryonic stage	No of ET	Pregnancies conceived	Intervention	Outcome

ICSI	Assisted hatching	Embryo biopsy

No	No	No	Cleavage	4	MCTA triplets	Reduction	DCDA miscarriage

DCDA twins

No	No	No	Cleavage	3	MCTA triplets	Nil	Delivery ?weeks

Yes	No	No	Blastocyst	3	MCTA triplets	Reduction	DCDA delivery 36 weeks

DCDA twins

Yes	Yes	No	Blastocyst	2	MCTA triplets	Nil	CS at week 31

Yes	Yes	No	Cleavage	3	MCTA triplets	Reduction	Singleton CS at week 38

Singleton

Yes	Yes	No	Cleavage	3	MCTA triplets	Nil	CS at week 34

Yes	No	No	Blastocyst	2	MCTA triplets	Reduction	Ongoing MCDA pregnancy 22 weeks

MCDA twins

Yes	No	No	Blastocyst	2	MCTA triplets	Reduction	Ongoing MCDA pregnancy 20 weeks

MCDA twins

Yes	Yes	No	Cleavage	1	MCTA triplets	Nil	Ongoing pregnancy

16 weeks

No	No	No	Blastocyst	2	MCTA triplets	Nil	Ongoing pregnancy 7 weeks

No	No	No	Blastocyst	2	MCTA triplets	Termination

No	No	No	Blastocyst	1	MCTA triplets	Termination

Yes	No	No	Blastocyst	1	MCTA triplets	Nil	CS at 33 weeks

No	No	No	Blastocyst	1	MCTA triplets	Nil	CS at 32 weeks

Yes	Yes	No	Day 4	3	MCTA triplets	Reduction	Singleton CS at 38 weeks

singleton

Yes	No	Yes	Day 4	3	MCTA triplets	Reduction	Singleton delivery at 38 weeks

singleton

No	No	No	Cleavage	2	MCQA	Nil	Miscarriage

No	No	No	Blastocyst	2	MCTA	Termination

Yes	No	Yes	Day 4	1	MCQA	Reduction	MCDA CS at 35 + 6 weeks

No	No	No	Blastocyst	1	MCTA	Reduction	Ongoing MCDA pregnancy


Location and day	Central station	Adjacent to patient

John Radcliffe Hospital Adult ICU weekday	58.4 dB	59.7 dB

John Radcliffe Hospital Adult ICU weekend	59.1 dB	59.5 dB

Royal Berkshire Hospital ICU weekday	58.7 dB	59.9 dB

Royal Berkshire Hospital ICU weekend	57.7 dB	58.5 dB

Wycombe General Hospital ICU weekday	52.4 dB	55.4 dB

Wycombe General Hospital ICU weekend	51.3 dB	54.1 dB

John Radcliffe Neurosciences ICU weekday	58.0 dB	58.8 dB

Churchill Hospital Adult ICU weekend	55.7 dB	55.4 dB

Location and day	Central station

John Radcliffe Hospital Adult ICU weekday	58.4 dB

John Radcliffe Hospital Adult ICU weekend	59.1 dB

Royal Berkshire Hospital ICU weekday	58.7 dB

Royal Berkshire Hospital ICU weekend	57.7 dB

Wycombe General Hospital ICU weekday	52.4 dB

Wycombe General Hospital ICU weekend	51.3 dB

John Radcliffe Neurosciences ICU weekday	58.0 dB

Churchill Hospital Adult ICU weekend	55.7 dB

Adjacent to patient

59.7 dB

59.5 dB

59.9 dB

58.5 dB

55.4 dB

54.1 dB

58.8 dB

55.4 dB


Gene ID	Description	Lineagea	dN/dS

			A	B	C	D	E

YDR197W	Mitochondrial translational activator of the COB mRNA	B	0.078	1.472	0.092	0.088	0.131

YER174C	Hydroperoxide and superoxide- radical responsive glutathione- dependent oxidoreductase	B	0.086	1.243	0.033	0.102	0.044

YFR041C	telomere maintenance	B	0.132	1.138	0.054	0.111	0.071

YGL119W	Protein required for ubiquinone (coenzyme Q) biosynthesis and for respiratory growth	B	0.045	4.607	0.044	0.073	0.078

YMR006C	glycerophospholipid metabolism	C	0.060	0.036	2.788	0.060	0.052

YPL248C	galactose metabolism; DNA- dependent regulation of transcription	C	0.175	0.240	1.078	0.145	0.170


Code	Before wetting	After wetting	Increased by

CH	220 μm	410 μm	46.34%

MCG	225 μm	310 μm	27.42%

F	240 μm	440 μm	45.45%

MF	300 μm	380 μm	21.05%

Before wetting	After wetting	Increased by

220 μm	410 μm	46.34%

225 μm	310 μm	27.42%

240 μm	440 μm	45.45%

300 μm	380 μm	21.05%


Simulated Ontario Illness Attack Rates by the Percentage of Adults 53+ Years Old with Pre-existing Immunity1		Calibrated Attack Rates (AR)


	Child demographics	Maternal psychopathology

Maternal Abuse Group	Age, M ± SD	Sex, % female	PTSD, M ± SD	Depression, M ± SD

Physical Childhood Abuse

 Low (n = 22)	8.9 ± 2.0	54.5	11.5 ± 11.0	17.3 ± 10.0

 High (n = 11)	10.7 ± 2.0*	45.5	22.3 ± 13.9*	28.5 ± 14.7*

Emotional Childhood Abuse

 Low (n = 24)	8.9 ± 2.1	54.2	11.9 ± 10.7	16.7 ± 9.7

 High (n = 9)	11.1 ± 1.4*	44.4	23.7 ± 15.0*	32.2 ± 13.6**

Sexual Childhood Abuse

 Low (n = 17)	8.6 ± 2.2	52.9	7.7 ± 7.9	14.8 ± 8.5

 High (n = 16)	10.4 ± 1.8*	50.0	22.7 ± 12.8**	27.7 ± 13.3**


 	Enthalpy of desolvation, ΔdesolvH (kJ mol−1) from DSC	Enthalpy of desolvation, ΔdesolvH (kJ mol−1) calculated from equation 4

Atorvastatin (ATC)	-

Solvate- I (ATC + 0.5 Isopropyl alcohol)	24.20	25.93

Solvate- II (ATC + THF)	51.47	57.17

Solvate- III (ATC + Ethanol)	44.69	34.39

Solvate- IV (ATC + 0.5 t-butanol)	78.85	78.31

Solvate- V (ATC + methanol)	26.27	26.70

Solvate-VI (ATC + 1 Acetone +0.5 Ethanol)	56.74	52.01

Solvate-VII (ATC + 0.5 Ethanol + Water)	104.64	103.96

Solvate- VIII (ATC + 1- butanol)	28.56	31.81

	Enthalpy of desolvation, ΔdesolvH (kJ mol−1) from DSC	Enthalpy of desolvation, ΔdesolvH (kJ mol−1) calculated from equation 4

Atorvastatin (ATC)	-

Solvate- I (ATC + 0.5 Isopropyl alcohol)	24.20	25.93

Solvate- II (ATC + THF)	51.47	57.17

Solvate- III (ATC + Ethanol)	44.69	34.39

Solvate- IV (ATC + 0.5 t-butanol)	78.85	78.31

Solvate- V (ATC + methanol)	26.27	26.70

Solvate-VI (ATC + 1 Acetone +0.5 Ethanol)	56.74	52.01

Solvate-VII (ATC + 0.5 Ethanol + Water)	104.64	103.96

Solvate- VIII (ATC +		31.81


Behavioral trait

Time spent in predator channel (proportion)	0.44 ± 0.01n = 11

Direct approaches toward predator (proportion)	0.32 ± 0.03n = 11

Startle responses	0.52 ± 0.06n = 11

Number of freezes	0.99 ± 0.15n = 11

Relative swimming activity	0.17 ± 0.01n = 11

Behavioral trait

ard predator (proportion)	0.32 ± 0.03n = 11

Startle responses	0.52 ± 0.06n = 11

Number of freezes	0.99 ± 0.15n = 11

Relative swimming activity	0.17 ± 0.01n = 11


Analyte	FNa	FP

Original result (total)	Discrepant investigation outcomeb	Original result (total)	Discrepant investigation outcome

RP2 confirmed (TN)	RP2 unconfirmed (FN)	RP2 confirmed (TP)	RP2 unconfirmed (FP)

Viruses

Adenovirus	4	1	3	48	40	8

Coronavirus 229E	1	1	0	5	0	5

Coronavirus HKU1	0			12	3	9

Coronavirus NL63	0			10	3	7

Coronavirus OC43	8	2	6c	5	2	3

Human metapneumovirus	2	2	0	8	6	2

Human rhinovirus/enterovirus	11	6	5	77	33	44

Influenza virus A	0			0

H1	0			0

H1-2009	0			0

H3	0			0

Influenza virus B	0			2	2	0

Middle East respiratory syndrome coronavirus (MERS-CoV)	0			0

Parainfluenza virus 1	0			1	0	1

Parainfluenza virus 2	1	1	0	8	5	3

Parainfluenza virus 3	2	0	2	10	4	6

Parainfluenza virus 4	0			7	1	6

Respiratory syncytial virus	1	1	0	24	8	16

Bacteria

Bordetella parapertussis (IS1001)	1	0	1	0

Bordetella pertussis (ptxP)	1	0	1	1	1	0

Chlamydia pneumoniae	0			1	1	0

Mycoplasma pneumoniae	1	0	1	5	5	0

Total	33	14	19	224	114	110


Clinical profile	Asthmatics (all subject)	AIA	ATA

Current Smoker (%)	27.70	21.47	30.07

Positive rate of skin test (%)	56.42	52.76	57.81


	Survivors(n = 45)	Nonsurvivors(n = 43)

Age (mean ± SD)	42 (35-50)	38 (29-46)

Male gender (%)	36 (80%)	31 (72%)

Location before ICU (ward, %)	24 (53%)	29 (67%)

Performance status 3 or 4	1 (0-2)	2 (1-3)

CD4 count <50 mm3 (%)	20 (44%)	21 (49%)

Length of time from AIDS diagnosis	39 (2-92)	50 (2-85)

Recent (<3 months) AIDS diagnosis	13 (29%)	13 (30%)

HAART use	20 (44%)	20 (46%)

SAPS II expanded (points)	44 (37-54)	54 (46-67)b

SOFA D1 (points)	4 (1-7)	7 (4-10)b

Mechanical ventilation	17 (38%)	36 (84%)b

Use of vasopressors on day 1	6 (13%)	15 (30%)a

Renal support	3 (7%)	13 (30%)b

Severe sepsis/septic shock (%)	15 (33%)	29 (67%)b

ICU length of stay (days)	9 (5-17)	10 (4-14)

Hospital length of stay (days)	24 (12-58)	15 (10-24)a

	Survivors(n = 45)	Nonsurvivors(n = 43)

Age	42 (35-5	38

 (mean ± SD)	0)	 (29-46)

Male gender (%)	36 (80%)	31 (72%)

Location before ICU (ward, %)	24 (53%)	29 (67%)

Performance status 3 or 4	1 (0-2)	2 (1-3)

CD4 count <50 mm3 (%)	20 (44%)	21 (49%)

Length of time from AIDS diagnosis	39 (2-92)	50 (2-85)

Recent (<3 months) AIDS diagnosis	13 (29%)	13 (30%)

HAART use	20 (44%)	20 (46%)

SAPS II expanded (points)	44 (37-54)	54 (46-67)b

SOFA D1 (points)	4 (1-7)	7 (4-10)b

Mechanical ventilation	17 (38%)	36 (84%)b

Use of vasopressors on day 1	6 (13%)	15 (30%)a

Renal support	3 (7%)	13 (30%)b

Severe sepsis/septic shock (%)	15 (33%)	29 (67%)b

ICU length of stay (days)	9 (5-17)	10 (4-14)

Hospital length of stay (days)	24 (12-58)	15 (10-24)a


Characteristics	Correlation coefficient (r)	P value

AA	SS	AA	SS

Age 	−0.752	−0.744	0.000	0.000

BMI	0.120	0.386	0.241	0.000

Subischial leg length	−0.922	−0.919	0.000	 0.000

Sitting height	−0.728	−0.670	0.000	0.000

Weight	−0.565	−0.700	0.000	0.000

Characteristics	Correlation coefficient (r)

AA

Age	−0.752

BMI	0.120

Subischial leg length	−0.922

Sitting height	−0.728

Weight	−0.565


Variable	β	SE	Ventricular septal defects (yes vs. no)	P value

Odds ratio	95% confidence interval

NBL	−0.37	0.12	0.69	0.55 to 0.87	0.001

UA PI	 2.09	0.32	8.10	4.31 to 15.21	<0.0001

MCA PI	−1.37	0.38	0.25	0.12 to 0.54	<0.0001

Variable	β	SE	Ventricular septal defects (yes vs. no)	P value

Odds ratio	95% confidence interval

NBL	−0.3	0.12		0.55	0

Variable	β	SE	Ventricular septal defects (yes vs. no)	P value

Odds ratio	95% confidence interval

	7		0.69	 to 0.87	.001

UA PI	2.09	0.32	8.10	4.31 to 15.21	<0.0001

MCA PI	−1.37	0.38	0.25	0.12 to 0.54	<0.0001


 	RSV group A	 	RSV group B

 	Global	Dadaab	Global	Dadaab

Period (years)	2006-11	2007-11	2006-11	2007-11

Total Sequences@	649	182	504	108

Overall % Genetic distance	6.9	1.4	4.7	2.4

Sequences Unique (%)*	338 (52.1)	39 (21.4)	361(71.6)	24 (22.2)

Number of genotypes identified	2	2	4	1


Technique	N	TP	TN	FN	k	Sensitivity	Specify%	Specify%	PPV%	NPV%	Accuracy%


Pupil size (mm)	n	Nurses’ estimationsa (mm)	Pupillometer measurementsa (mm)	P value	Spearman's coefficient (95 % CI)	P value

<2	61	2 (2–2)	1.8 (1.6–1.8)	0.057	0.39 (0.15–0.59)	0.002


 	n	Mean	Std. Deviation

FRACTURE STRENGTH	80	1016.6670	171.58485


	1997

Subconjunctival hemorrhage	92 (28.75%)

Conjunctivitis	108 (33.75%)

Keratitis	20 (6.25%)

Eyelid-related disorders	61 (19.06%)

Contact lens-related disorders	39 (12.19%)

Total	320 (100%)


Spot no.	Identity	MW (Da)	GenBank acc. no.	FC

1	Ser/Thr-specific protein phosphatase 2A A regulatory subunit β isoform (Medicago sativa subsp.×varia)	65161.6	AAG29594	0.647

2	Pyruvate kinase (Lactuca sativa)	56174.9	ABS87384	0.481

3	Branched-chain amino acid aminotransferase, putative (Ricinus communis)	45159.9	XP_002530599	0.541

4	Glucose-6-phosphate isomerase (Zea mays)	68403.5	NP_001147983	1.837

5	Actin (Phaseolus acutifolius)	33121.3	AAZ95077	2.277

6	Dehydrin (Phaseolus vulgaris)	22955.6	AAB00554	2.048

7	Dehydrin (Phaseolus vulgaris)	22955.6	AAB00554	1.846

8	Lactoylglutathione lyase, putative/glyoxalase I, putative (Arabidopsis thaliana)	20830.4	NP_001030996	2.414

9	Dehydrin (Phaseolus vulgaris)	22955.6	AAB00554	2.438

10	Dehydrin (Phaseolus vulgaris)	22955.6	AAB00554	1.625

Spot no.	Identity

1	Ser/Thr-specific protein phosphatase 2A A regulatory subunit β isoform (Medicago sativa subsp.×varia)

2	Pyruvate kinase (Lactuca sativa)

3	Branched-chain amino acid aminotransferase, putative (Ricinus communis)

4	Glucose-6-phosphate isomerase (Zea mays)

5	Actin (Phaseolus acutifolius)

6	Dehydrin (Phaseolus vulgaris)

7	Dehydrin (Phaseolus vulgaris)

8	Lactoylglutathione lyase, putative/glyoxalase I, putative (Arabidopsis thaliana)

9	Dehydrin (Phaseolus vulgaris)

10	Dehydrin (Phaseolus vulgaris)


	Dorsal

1 (pSN)

L

pHipp	−0.05

aHipp	−0.03


Day	Haematocrit	Haemoglobin

	Control	Group A	Group B	Control	Group A	Group B

	28.3 ± 	28.2 	28.4 ± 2	9.2	9.	9.2 ±


	CS-cineCMR	3D-HR-CMR(ref)	Diff	Diff [%]

	Volume [ml]	Volume [ml]	Volume [ml]

Patient 1	62.5	59.0	3.5	5.7 %

Patient 2	61.5	71.0	−9.5	−14.3 %

Patient 3	395.0	397.0	−2.0	−0.5 %


Study sites	Sampling units (classes of listed educational institutions below, wards of Village Development Committee (VDCa ))	Sampling unit population	Sample size (i.e. number of respondents)	Sample size (%)

Bachhayauli	Class 12, Jhuwani Higher Secondary School, Bachhayauli 09, Chitwan	33 (10 students, 23 teachers)b	25 (10 students, 15 teachers)	76

Ward number 3, Bachhayauli VDCa, Chitwan	148 household headsc	25 (household heads)	17

Baghauda	Bachelor’s degree of Business Studies, 1st year, Madi Multiple Campus, Tribhuvan University, Baghauda 03, Chitwan	44 (24 students, 20 teachers)b	25 (10 students, 15 teachers)	57

Ward number 5, Baghauda VDCa, Chitwan	87 household headsc	25 (household heads)	29

Meghauli	Class 11 and 12, Janaki Higher Secondary School, Telauli, Meghauli 05, Chitwan	60 (28 students, 32 teachers)b	25 (10 students, 15 teachers)	42

Ward number 6, Meghauli VDCa, Chitwan	43 household headsc	25 (household heads)	58

	Total	415	150 (30 students, 45 teachers, 75 villagers)	36

Study sites	Sampling units (classes of listed educational institutions below, wards of Village Development Committee (VDCa ))	Sampling unit population	Sample size (i.e. number of respondents)	Sample size (%)

Meghauli	Class 11 and 12, Janaki Higher Secondary School, Telauli, Meghauli 05, Chitwan	60 (28 students, 32 teachers)b	25 (10 students, 15 teachers)	42

Ward number 6, Meghauli VDCa, Chitwan	43 household headsc	25 (household heads)	58

	Total	415	150 (30 students, 45 teachers, 75 villagers)	36


parameter

data collection statistics

resolution (Å) (range)

space group

cell dimensions for a, b, c (Å)

α, β, γ (°)

no. reflectionsa

observed

unique

mean I/σ(I)

completeness (%)

Rmerge (%)

B-factor from Wilson plot (Å2)

refinement statisticsb

Rcryst (%)

Rfree (%)

no. non-hydrogen atoms

total

protein

ligands

water

average B-factor values

total

protein (Å2)

ligands (Å2)

solvent (A°2)

RMSD from ideal geometry

bond length (Å)

bond angle (°)

Ramachandran plot

% of residues in preferred regions

% of residues in disallowed regions


First examiner	Hand	Thyroid 	Eye lens	Chest	No. of Film	Exposure time (min)	X-ray tube location

Present study	27.0	5.0	3.0	6.0	2.5	2.4	Overcouch

Buls et al [14]	0.64	0.45	0.55	nd	4	6.0	Overcouch

Naidu et al. [9]*	NR	0.2	0.04	NR	4.6	5.9	Overcouch

Sulieman et al. [3] 	27.2	5.4	3.8	6.2	2.6	2.9	Overcouch

Oztas et al. [10]	20.0	2.0	82.0	NR	1.7	5.7	undercouch

First examiner	Hand	Thyroid	Eye lens	Chest	No. of Film	Exposure time (min)	X-ray tube location

Sulieman et al. [3]	27.2	5.4	3.8	6.2	2.6	2.9	Overcouch

Oztas et al. [10]	20.0	2.0	82.0	NR	1.7	5.7	undercouch


Population n	Age (years)/avg ± SD range	Mass (kg)/Avg ± SD range	Stature (m)/Avg ± SDr ange	BMI/Avg ± SD range

10(f = 3, m = 7)	35.8 ± 8.822–53	53.6 ± 10.444–73	1.60 ± 0.091.45–1.75	20.7 ± 3.116.4–25.9

Population n	Age (years)/avg ± SD range	Mass (kg)/Avg ± SD range	Stature (m)/Avg ± SDr ange	BMI/Avg ± SD range

10(f =	35.8 ± 8.822–53	53.6 ± 1	1.60 ± 0.091.45–1.7	20.7 ± 3.116.4–


Parameter	Pre-control	Post-control

Vital signs

Temperature (°C)	26.86 ± 0.06	26.35 ± 0.07

Heart rate (beats/min)	52.80 ± 1.25	51.60 ± 1.05

Respirations (breaths/min)	4.85 ± 0.59	3.93 ± 0.34

Timing parameters (min; measured from time of first disturbance)

Bleeding time	1.94 ± 0.08	3.05 ± 0.35

Handling time	11.98 ± 0.72	9.63 ± 0.53

CG4 lag time	2.54 ± 0.50	1.52 ± 0.14

CG8 lag time	7.01 ± 0.81	5.24 ± 0.14

Haematological data

Heterophils (%)	64.87 ± 1.97	68.93 ± 2.49

Lymphocytes (%)	32.47 ± 1.73	29.00 ± 2.41

Monocytes (%)	1.93 ± 0.32	1.33 ± 0.21

Eosinophils (%)	0.73 ± 0.18	0.67 ± 0.23

Heterophils (cells/μl)	2877 ± 202.6	3789 ± 570.4

Lymphocytes (cells/μl)	1412 ± 87.9	1466 ± 152.2

Monocytes (cells/μl)	85 ± 15.8	63 ± 10.6

Eosinophils (cells/μl)	33 ± 8.4	26 ± 8.2


Funcats	Number of genes assigned an InterAct class	Number of InterAct class 0000 genes	p-value

All funcats	3,447	1,089	-

Metabolism	496	120	6.0 × 10-4

Protein synthesis	218	55	2.6 × 10-2

Energy	125	21	1.34 × 10-4

Funcats	Number of genes assigned an InterAct class	Number of InterAct class 0000 genes	p-value

Energy	125	21	1.34 × 10-4


Factor	Coefficients	Standard error	t-value	P value

Intercept	−249.9	80.11	−3.120	0.02059


Characteristics	No. of errors	%

Gender

Male	860	64.5

Female	473	35.5

Total	1333	100

Age group

Less than 1 year	593	44.5

1-3 years	249	18.7

4-6 years	167	12.5

7-9 years	43	3.2

10-12 years	281	21.1

Total	1333	100

Administration route

Intravenous	669	50.2

Oral	342	25.7

Inhalation	222	16.6

Topical	60	4.5

Subcutaneous	24	1.8

Intramuscular	16	1.2

Total	1333	100

Location

PICU	452	33.9

Pediatric wards	881	66.1

Total	1333	100


Drugs:	n	%

Adefovir	1	1.9

Boceprevir	1	1.9

Entecavir	9	17.3

Interferon	4	7.7

Pegylated interferon	9	17.3

Lamivudine	4	7.7

Ribavirin	13	25.0

Telapravir	1	1.9

Tenofovir	10	19.2

Total	52	100


Counter-Intuitive Modules	% Total

verage	.41

Stdev	13.03


Variables	Entire sample (100%)	Multiple sclerosis§ (46%)	Depressive disorders (32%)	Psychotic and other disorders (22%)*	Statistics (Pearson’s χ2 or ANOVA)

Gender, %	 	 	 	 	p < .0001

Women	68	78	66	56

Men	32	22	34	44

Age, years (Mean, standard deviation)	41 ± 13	43 ± 11	41 ± 14	38 ± 13	F = 5.2; p = .006

Family status, %	 	 	 	 	p < .0001

Married	58	56	50	67

With partner, not married	22	17	34	21

Divorced	11	19	0	0

Single	10	8	16	12

Educational level, %	 	 	 	 	p = .007

Through Grade 9	24	22	26	26

Through Grade 10	33	33	37	31

High school diploma	38	36	37	41

Other	5	9	0	1

Spiritual/religious self-categorization, %	 	 	 	 	n.s.

R + S + (religious and spiritual)	15	12	16	18

R + S- (religious, not spiritual)	21	19	24	21

R-S + (not religious but spiritual)	15	16	14	14

R-S- (neither religious nor spiritual)	50	54	47	46

Engagement in spiritual activities (0–100)**

Existential practices	54 ± 25	43 ± 11	60 ± 23	62 ± 22	F = 23.2; p < .0001

Humanistic practices	65 ± 19	65 ± 19	66 ± 16	65 ± 20	F = 0.1; n.s.

Religious practices	26 ± 24	22 ± 24	31 ± 25	27 ± 23	F = 5.1; p = .007

Spiritual (MB) practices	19 ± 22	21 ± 24	15 ± 17	19 ± 21	F = 2.6; n.s.

Gratitude/Awe	42 ± 24	44 ± 22	38 ± 25	43 ± 25	F = 2.2; n.s.

Life satisfaction Sum Score (BMLSS-10) (0-100)	54.6 ± 22.3	69.1 ± 17.1	42.5 ± 15.6	42.5 ± 20.7	F = 123.1; p < .0001

Life Satisfaction Subdimensions (0–6)

Family life	3.62 ± 1.83	4.60 ± 1.45	2.83 ± 1.55	2.84 ± 1.84	F = 66.0; p < .0001

Friendships	3.70 ± 1.73	4.49 ± 1.43	3.03 ± 1.64	3.06 ± 1.73	F = 46.7; p < .0001

Work situation	2.82 ± 1.96	3.69 ± 1.72	2.30 ± 1.75	2.18 ± 1.98	F = 28.2; p < .0001

Myself	2.81 ± 1.80	4.00 ± 1.40	1.82 ± 1.44	1.88 ± 1.53	F = 121.5; p < .0001

Where I live	4.01 ± 1.64	4.55 ± 1.42	3.50 ± 1.61	3.62 ± 1.71	F = 22.1; p < .0001

Life in general	3.32 ± 1.69	4.39 ± 1.20	2.21 ± 1.37	2.32 ± 1.66	F = 142.6; p < .0001

Financial situation	3.24 ± 1.83	3.93 ± 1.55	2.82 ± 1.76	2.59 ± 1.92	F = 29.6 ; p < .0001

Future prospects	2.92 ± 1.60	3.64 ± 1.29	2.22 ± 1.49	2.43 ± 1.66	F = 43.5; p < .0001

Health situation	2.45 ± 1.62	3.20 ± 1.49	1.89 ± 1.39	1.77 ± 1.47	F = 50.3; p < .0001

Abilities to deal withDaily life activities	3.07 ± 1.62	4.03 ± 1.33	2.29 ± 1.26	2.24 ± 1.47	F = 94.8; p < .0001


 	 	 	 	 	IOP	Visual acuity

Patient code	Gender	Age Dx	Diagnosis	Gly326Ser	RE	LE	RE	LE	Surgical procedure

G62	Male	59/65	OHT/POAG	yes	30	30	20/40	20/40	Trabeculectomy LE

01A	Female	65	Blind by POAG	yes	ptosis	20	HM	HM	-

03A	Female	63	OHT with tendency to angle closure	yes	26	20	20/30	20/30	Iridotomy

24A	Male	72	Advanced POAG	yes	26	26	HM	20/40	-

05A	Male	75	Pseudo exfoliation Glaucoma	no	25	17	-	20/40	Trabeculectomy, cataract surgery

08A	Male	76	POAG	no	22	23	20/50	20/40	Trabaculoplasty

					IOP	Visual acuity

Patient code	Gender	Age Dx	Diagnosis	Gly326Ser	RE	LE	RE	LE	Surgical procedure

G62		59	OHT/P	y	30		2	20/40	Trabe

	Male	/65	OAG	es		30	0/40		culectomy LE

01A	Female	65	Blind by POAG	yes	ptosis	20	HM	HM	-

03A	Female	63	OHT with tendency to angle closure	yes	26	20	20/30	20/30	Iridotomy

24A	Male	72	Advanced POAG	yes	26	26	HM	20/40	-

05A	Male	75	Pseudo exfoliation Glaucoma	no	25	17	-	20/40	Trabeculectomy, cataract surgery

08A	Male	76	POAG	no	22	23	20/50	20/40	Trabaculoplasty


	cis-acting	trans-acting

KS p-value 10-6 - 10-15	4,484	646

	cis-acting	trans-acting

KS p-value 10-15 - 10-30	5,311	500


Parameter	Correct

Study 1, No. (%)	Study, No. (%)	p

Registration of insertion date	337 (42.3)	339 (50.1)	0.003

Registration of daily surveillance	779 (97.7)	660 (98.2)	0.52

Registration of dressing change date	322 (41.2)	328 (49.1)	0.003

Registration of set replacement date	74 (45.4)	65 (43.3)	0.71

Use of connectors (split-septum) in all hubs	660 (83.7)	615 (92.2)	<0.001

Parameter	Study 1, No. (%)	Study, No. (%)	p

Registration of insertion date	337 (42.3)	339 (50.1)	0.003

Registration of daily surveillance	779 (97.7)	660 (98.2)	0.52

Registration of dressing change date	322 (41.2)	328 (49.1)	0.003

Registration of set replacement date	74 (45.4)	65 (43.3)	0.71

Use of connectors (split-septum) in all hubs	660 (83.7)	615 (92.2)	<0.001


Characteristics	LGSOCNo. of patients (%)	HGSOCNo. of patients (%)	p values

All cases	25	55

Mean Age, years (± SEM)	49.8 ± 3.0	56.8 ± 1.5	0.03

Type of primary surgery

 Cytoreduction	25	55	–

Residual tumor after primary surgery (cm)

 0	22	36	0.06#

 < 1	3	14

 > 1	0	5

FIGO Stage

 I/II	10 (40)	8 (15)	0.01

 III/IV	15 (60)	47 (85)

Primary chemotherapy

 None	3 (12)	1 (1.8)	0.08§

 Platinum/paclitaxel	17 (68.0)	48 (87.3)

 Platinum-based	4 (16.0)	5 (9.1)

 Other	1 (4)	1 (1.8)


	p-Nephrin	Nck (with p-Nephrin)	Nck (with p-TIR)	N-WASP

Null hypothesis	Single Exp.	Single Exp.	Single Exp.	Single Exp.

Alternate hypothesis	Double Exp.	Double Exp.	Double Exp.	Double Exp.

p value	<0.0001	<0.0001	<0.0001	<0.0001

Conclusion (alpha = 0.05)	Reject null hypo.	Reject null hypo.	Reject null hypo.	Reject null hypo.

Preferred model	Double Exp.	Double Exp.	Double Exp.	Double Exp.

F (DFn, DFd)	64.16 (2282)	47.33 (2635)	46.72 (2379)	48.64 (2379)

	p-Nephrin	Nck (with p-Nephrin)

Null hypothesis	Single Exp.	Single Exp.

Alternate hypothesis	Double Exp.	Double Exp.

p value	<0.0001	<0.0001

Conclusion (alpha = 0.05)	Reject null hypo.	Reject null hypo.

Preferred model	Double Exp.	Double Exp.

F (DFn, DFd)	64.16 (2282)	47.33 (2635)

Nck (with p-TIR)	N-WASP

Single Exp.	Single Exp.

Double Exp.	Double Exp.

<0.0001	<0.0001

Reject null hypo.	Reject null hypo.

Double Exp.	Double Exp.

46.72 (2379)	48.64 (2379)


	Talairach coordinates

	Hemisphere	BA	x	y	z	Volume (mm3)	Mean t

REGION OF ACTIVATION

Medial frontal gyrus	Left/Right	6/8	5	18	43	2590	5.40

Anterior insula	Right	13	41	18	5	4015	5.67

Anterior insula	Left	13	−30	18	5	1153	5.13

Dorsolateral prefrontal gyrus	Right	9/10	38	42	27	888	4.94

Precentral gyurs	Right	9	43	26	34	1262	5.10

Middle frontal gyrus	Right	9	45	12	36	2422	5.18

Middle frontal gyrus	Left	9	−41	29	37	67	4.72

Middle temporal gyrus	Right	21	56	−25	−5	191	4.86

Inferior parietal lobe	Right	40	48	−44	37	2744	5.42

Inferior parietal lobe	Left	40	−46	−37	41	595	5.05

Precuneus	Right	7	10	−68	39	299	5.01

Nucleus caudatus	Right		13	8	12	224	5.38

Thalamus	Right		10	−12	10	113	4.82

Thalamus	Left		−7	−16	9	131	5.01

REGION OF DEACTIVATION

Anterior cingulate gyrus	Left/Right	32	−2	36	−3	3226	−5.23

Superior frontal gyrus	Left	8	−17	26	45	315	−4.90

Posterior cingulate gyrus	Left/Right	30	−2	−53	20	560	−5.21


Variable	Rater	Group activity	Control

	Mean	SD	Mean	SD

'Engagement'	TR	3.55	1.41	2.72	1.96

Observer	3.73	1.35	3.31	1.7

Positive mood	TR	2.48	1.07	1.76	1.28

Observer	1.52	1.07	1.24	1.29

Asleep	TR	1.14	1.62	1.87	2.15

Observer	1.19	1.63	1.48	2.09


	B. subtilis	S. aureus	A. niger	S. cerevisiae

(a) Activity per full feces sample

Feces producer (FP)	P = 0.440	P = 0.098	P = 0.005	P <0.0001

Mother-offspring interactions (MO)	P = 0.808	P = 0.104	P = 0.342	P = 0.051

FP : MO	P = 0.553	P = 0.934	P = 0.068	P = 0.215

(b) Activity per mg of feces

Feces producer (FP)	P <0.0001	P = 0.008	P = 0.095	P = 0.080

Mother-offspring interactions (MO)	P = 0.813	P = 0.575	P = 0.052	P = 0.078

FP : MO	P = 0.812	P = 0.731	P = 0.037	P = 0.089


Disease stage	Number of patients	HU, IFN or combination pretreatment months from diagnosis median (range)	Months on imatinib median (range)	WBC x109/L PB median (range) PLT x109/L PB median (range)	Blasts in PB (%) median (range)	Ph+ cells (%) median (range)	BCR-ABL (%) median (range)	BCR-ABL KD mutation Number of patients

Dg	13	NA	NA	67 (22-457)	2 (1-5)	100	132 (61-312)	NA

				481 (130-824)

AP/BC	12	24 (2-106)	24 (8-55)	34 (1.17-147)	18 (8-76)	100	510 (103-2500)	3

				81 (14-562)

Hr	15	18 (1-66)	22 (10-54)	16 (6-28)	10; 12	100 (32-100)	80 (23-827)	15

				448 (71-1779)

TF	14	14 (1-68)	18 (12-67)	Phy	0	100 (40-100)	32 (11-91)	4

				Phy


	Influenza, Tdap, HZ vaccines (2014)	Influenza, Tdap, HZ, pneumococcal vaccines (2014)

	Aged 60-64 years	Aged ≥65 years

	% (95% CI)	% (95% CI)

Overall complianceb	6.61 (5.94, 7.28)	11.21 (9.51, 12.91)


 	Dictionary	Token features	Linguistic features	Semantic features

 	 	 	 	TUI	CUI

Baseline I	 	 	 	X

Baseline II	X

Experiment I	X	X	X

Experiment II	X	X	X	X

Experiment III	X	X	X	 	X


First author, [Ref] year, country	Study design	No. of case/controls (cohort)	Exposure category	Risk estimates (95% CI)	Adjustment for confounders

Age	BMI	Parity	HRT	OC use

Neill et al. [15], 2013, Australia	Population-based case-control	1398/740	Ever vs. Never≥ 2 week vs. Never	1.19 (0.86−1.65)0.77 (0.41−1.45)	√	√	√	√	√

Setiawan et al. [16], 2012, USA	Cohort	620/64000	Ever vs. Never≥ 6 years vs. Never	0.96 (0.81−1.13)0.80 (0.61−1.06)	√	√	√	√	√

Walter et al. [17], 2011, USA*	Cohort	214/32059	Ever vs. Never≥4 d/week and ≥ 4 years vs. Never	1.05 (0.72−1.54)0.99 (0.48−2.01)	√	√	×	√	×

Bodelon et al. [18], 2009, USA	Population-based case-control	410/356	Ever vs. Never≥ 10 years vs. Never	1.11 (0.70−1.77)1.80 (0.91−3.56)	√	√	×	√	×

Viswanathan et al. [19], 2008, USA*	Cohort	747/82971	Ever vs. Never≥ 6–7 d/weeks vs. Never	1.11 (0.70−1.77)0.86 (0.57−1.30)	×	√	√	√	√

Moysich et al. [20], 2005, USA	Hospital-based case-control	427/427	Ever vs. Never≥ 10 years vs. Never	0.96 (0.60−1.54)0.49 (0.15−1.60)	√	√	√	×	×

Friis et al. [21], 2002, Denmark	Cohort	58/26272	Ever vs. Never	1.10 (0.80−1.40)	×	×	×	×	×

First author, [Ref] year, country	Study design	No. of case/controls (cohort)	Exposure category	Risk estimates (95% CI)

Neill et al. [15], 2013, Australia	Population-based case-control	1398/740	Ever vs. Never≥ 2 week vs. Never	1.19 (0.86−1.65)0.77 (0.41−1.45)

Setiawan et al. [16], 2012, USA	Cohort	620/64000	Ever vs. Never≥ 6 years vs. Never	0.96 (0.81−1.13)0.80 (0.61−1.06)

Walter et al. [17], 2011, USA*	Cohort	214/32059	Ever vs. Never≥4 d/week and ≥ 4 years vs. Never	1.05 (0.72−1.54)0.99 (0.48−2.01)

Bodelon et al. [18], 2009, USA	Population-based case-control	410/356	Ever vs. Never≥ 10 years vs. Never	1.11 (0.70−1.77)1.80 (0.91−3.56)

Viswanathan et al. [19], 2008, USA*	Cohort	747/82971	Ever vs. Never≥ 6–7 d/weeks vs. Never	1.11 (0.70−1.77)0.86 (0.57−1.30)

Moysich et al. [20], 2005, USA	Hospital-based case-control	427/427	Ever vs. Never≥ 10 years vs. Never	0.96 (0.60−1.54)0.49 (0.15−1.60)

Friis et al. [21], 2002, Denmark	Cohort	58/26272	Ever vs. Never	1.10 (0.80−1.40)

Adjustment for confounders

Age	BMI	Parity	HRT	OC use

√	√	√	√	√

√	√	√	√	√

√	√	×	√	×

√	√	×	√	×

×	√	√	√	√

√	√	√	×	×

×	×	×	×	×


Resistance pattern	N

Double drugs

 MNZ + LVX	12 (28.6)

 MNZ + CAM	3 (7.1)

Triple drugs

 CAM + MNZ + LVX	5 (11.9)

Resistance pattern

Double drugs

MNZ + LVX

MNZ + CAM

Triple drugs

CAM + MNZ + LVX

N

Double drugs

12 (28.6)

3 (7.1)

Triple drugs

5 (11.9)


Gene name	AGI code	Forward primer sequence	Reverse primer sequence

ACL5	At5g19530	ACCGTTAACCAGCGATGCTTT	CCGTTAACTCTCTCTTTGATTC

XTH3	At3g25050	GTGTTTTTGTAGTAACGTTATGG	GGTTGGATTGAACCAAAGCAA

VND6	At5g62380	ATGGAAAGTCTCGCACACAT	CTCTTCCACATAACTCTTGG

VND7	At1g71930	CGATGCATCAATATGGCAAC	AGGGAAGCATCCAAGAGAAT

CNA	At1g52150	GGTATTTGCTGATTCATGAGC	ATGGTTTACACTTGACAGAGC

ATHB8	At4g32880	AGCGTTTCAGCTAGCTTTTGAG	CAGTTGAGGAACATGAAGCAGA

MP/ARF5	At1g19850	GATGATCCATGGGAAGAGTT	TAAGATCGTTAATGCCTGCG

TMO5L1	At1g68810	CACCACCAAAACGGATAAAG	CGTTTTGAGACGCATAGCTT

PIN1	At1g73590	CTTAGCACTGCGGTGATATT	TTGCTGAGCTCCTACTTAAG

PIN6	At1g77110	CTATCGTACAGGCTGCTCTA	CTCCTCAAGAACAACTCTTA

YUC2	At4g13260	ATGTGGCTAAAGGGAGTGAA	AACTTGCCAAATCGAAACCC

IRT1	At4g19690	GTCTAATCACTCTAGCCATTGA	TGTATACTCAGCCTGGAGGA

PXY/TDR	At5g61480	CGGTTACATTGCACCAGAAT	GCTTGTACACAACAACGCAA

SAC51	At5g64340	AATTGCCAGGCTGAGTACTT	GACCGACCTACTATATCCTT

ACT8	At1g49240	GTGAGCCAGATCTTCATTCGTC	TCTCTTGCTCGTAGTCGACAG


	Culprit plaque	Totals

	Acute rupture	Healing rupture	Stable plaque

N	51	5	16	72

Age, years ± SD	52 ± 11	52 ± 10	48 ± 8	51 ± 11

Men: women	47:4	5:0	14:2	66:6

White:Black	38:13	3:2	12:4	53:19

Heart weight, g ± SD	504 ± 127	605 ± 125	466 ± 87	511 ± 134

Diabetic	9	0	1	10

Hypertensive	13	4	5	22

Hypercholesterolemic	25	3	9	37

Smokers	26	3	7	36

Number of plaques studied	100*	7	28	135

 Acute ruptures	61	0	0	61

 Healing ruptures	8	0	0	15

 Thin cap FA	20	7	11	31

 FA	11	0	17	28


Integration Block	Frame Rate (frames per second)

L&K C 9 × 9 Integration Block	0.3

L&K C 9 × 9 SIB	0.9

L&K C 9 × 9 SIB	3.6

L&K ASM 9 × 9 SIB and propagation	11.9

L&K C 5 × 5 Integration Block	1.3

L&K C 5 × 5 SIB	3.3

L&K C 5 × 5 SIB and propagation	8.9

L&K ASM 5 × 5 SIB and propagation	28.8

Integration Block	Frame Rate (frames per second)

L&K C 9 × 9 Integration Block	0.3

L&K C 9 × 9 SIB	0.9

L&K C 9 × 9 SIB	3.6

L&K ASM 9	11.9

Integration Block	Frame Rate (frames per second)

 × 9 SIB and propagation

L&K C 5 × 5 Integration Block	1.3

L&K C 5 × 5 SIB	3.3

L&K C 5 × 5 SIB and propagation	8.9

L&K ASM 5 × 5 SIB and propagation	28.8


Characteristics	N	%

Median age, years (range)	62.1 (21.1–79.7)

Male / Female	65/44	59.6/40.4

Median Karnofsky performance status (range)	70 (30–90)

Extent of surgery

- Complete resection	82

- Partial resection	27	24.8

Radiotherapy	84	77.1

Median OS, months (range)	13.2 (1.5–141.4)

Median PFS, months (range)	7.9 (0.9–132.4)


A) Factors differentiating those who do / do not recover during follow up	Odds ratio (95% CI)	p-value	Interpretation

Ethnicity(Caucasian vs non-Caucasian)	14.19 (2.52, 122.63)	0.007	Non-Caucasians – less likely to recover from proteinuria

eGFR	1.04 (1.02, 1.08)	0.007	Low eGFR at proteinuria onset - less likely to recover

Azathioprine use	0.093 (0.01, 0.78)	0.044	Use of Azathioprine at proteinuria onset – less likely to recover

Haematological involvement	0.13 (0.03, 0.53)	0.007	Haematological involvement – less likely to recover

Cardiorespiratory involvement	11.22 (1.57, 107.54)	0.022	Cardiorespiratory involvement - more likely to recover

B) Factors influencing time to recovery from proteinuria	HR (95% CI)	p-value

Age (years)	1.38 (1.1, 1.8)	0.007	Younger patients - less likely to recover

eGFR	1.0 (1.0, 1.1)	0.036	Lower eGFR - less likely to recover

Haematological involvement	0.3 (0.1, 0.8)	0.016	Haematological involvement - less likely to recover

A) Factors differentiating those who do / do not recover during follow up	Odds ratio (95% CI)	p-value	Interpretation

Azathioprine use	0.093 (0.01, 0.78)	0.044	Use of Azathioprine at proteinuria onset – less likely to recover

Haematological involvement	0.13 (0.03, 0.53)	0.007	Haematological involvement – less likely to recover

Cardiorespiratory involvement	11.22 (1.57, 107.54)	0.022	Cardiorespiratory involvement - more likely to recover

B) Factors influencing time to recovery from proteinuria	HR (95% CI)	p-value

Age (years)	1.38 (1.1, 1.8)	0.007	Younger patients - less likely to recover

eGFR	1.0 (1.0, 1.1)	0.036	Lower eGFR - less likely to recover

Haematological involvement	0.3 (0.1, 0.8)	0.016	Haematological involvement - less likely to recover


	Original EpiPen	New-look EpiPen	Anapen

Step 1: Remove safety caps	Form a fist around EpiPen and remove gray safety cap	Form a fist around EpiPen and pull off blue safety release	1. Pull off black needle shield

2. Pull off gray safety cap from red button

Step 2: Place against thigh	Place black end against outer mid thigh (with or without clothing)	Place orange end against outer mid thigh (with or without clothing)	Place needle end firmly against outer mid-thigh (with or without clothing)

Step 3: Push and inject	Push down hard until a click is heard or felt and hold in place for 10 seconds	Push down hard until a click is heard or felt and hold in place for 10 seconds	Press red button so it clicks and hold in place for 10 seconds.

Step 4: Remove and massage site	Remove EpiPen and do not touch needle. Massage injection site for 10 seconds	Remove EpiPen. Massage injection site for 10 seconds.	Remove Anapen and do not touch needle. Massage injection site for 10 seconds.

	Original EpiPen	New-look EpiPen	Anapen

Step 1: Remove safety caps	Form a fist around EpiPen and remove gray safety cap	Form a fist around EpiPen and pull off blue safety release	1. Pull off black needle shield

2. Pull off gray safety cap from red button

Step 2: Place against thigh	Place black end against outer mid thigh (with or without clothing)	Place orange end against outer mid thigh (with or without clothing)	Place needle end firmly against outer mid-thigh (with or without clothing)

Step 3: Push and inject	Push down hard until a click is heard or felt and hold in place for 10 seconds	Push down hard until a click is heard or felt and hold in place for 10 seconds	Press red button so it clicks and hold in place for 10 seconds.

Step 4: Remov	Remove EpiPen and do not touch need	Remove EpiPen. Massage inject	Remove Anapen and do not touch needle. Massag

	Original EpiPen	New-look EpiPen	Anapen

e and massage site	le. Massage injection site for 10 seconds	ion site for 10 seconds.	e injection site for 10 seconds.


Shared by:	C. graminicola	Shared by:	C. sublineola

OrthoMCL	RBH	OrthoMCL	RBH

CgramCsubChigg	9281	9264	Cgram:Csub:Chigg	9323	9252

Cgram:Csub	1015	1018	Csub:Cgram	1036	1057

Cgram:Chiggs	473	560	Csub:Chiggs	333	500

Cgram only	134	1164	Csub only	456	2502

Not Characterized	1103	0	Not Characterized	2163	0

Total	12006	12006	Total	13311	13311

Shared by:	C. graminicola	Shared by:	C. sublineola

OrthoMCL	RBH	OrthoMCL	RBH

Total	12006	12006	Total	13311	13311


Pathways	Infection related	Pathways in

 	pathways	cancer

Gene No.	1082	326

Overlap between pathways in cancer and infection related pathways	169

Hum-Mtb targeted Human proteins Overlap with HP-PPI targeted human proteins	204	29

Overlap of the three datasets	20


n = 58	Mean ± SD	Quartiles25%50%75%

Leptin (ng/mL)	18.4 ± 9.3	10.5


Allele	Study	Proportions of alleles	Adjusted‡ odds ratios of AD (95% CI, p)

		Controls	AD

HLA-B7	Previous†	10/112	26/110	3.1 (1.2–8.0, 0.02)


Space group	P21

Unit cell dimensions

a (Å)	42.2

b (Å)	64.3

c (Å)	48.6

β (°)	102.1

Number of molecules in the unit cell	2

Resolution range (Å)	36.0 - 1.2

The range of the highest shell	1.24 - 1.20

Total number of measured reflections	727277

Number of unique reflections	62459

Rsym (%)	5.0(22.1)

I/σ(I)	17.8(3.6)

Completeness of data (%)	98.5(87.1)

Rcryst (%)	15.8

Rfree (%) 5% of reflections	18.6

Protein atoms	2101

Water oxygen atoms	434

Phosphate ion atoms (1)	5

Atoms from PEG	40

R.m.s.d in bond lengths (Å)	0.008

R.m.s.d in bond angles (°)	1.2

R.m.s.d in torsion angles (°)	16.8

B-factors (Å2)

B-factor from Wilson plot (Å2)	12.3

Mean B-factor for main chain atoms (Å2)	11.2

Mean B-factor for side chain and water atoms (Å2)	19.2

Mean B-factor for all atoms(Å2)	15.8

Ramachandran's φ, ψ map

Residues in the most favoured regions (%)	90.4

Residues in the additionally allowed regions (%)	9.3

Residues in the generously allowed regions (%)	0.3

PDB ID	3MU7

Space group

Unit cell dimensions

a (Å)

b (Å)

c (Å)

β (°)

Number of molecules in the unit cell

Resolution range (Å)

The range of the highest shell

Total number of measured reflections

Number of unique reflections

Rsym (%)

I/σ(I)

Completeness of data (%)

Rcryst (%)

Rfree (%) 5% of reflections

Protein atoms

Water oxygen atoms

Phosphate ion atoms (1)

Atoms from PEG

R.m.s.d in bond lengths (Å)

R.m.s.d in bond angles (°)

R.m.s.d in torsion angles (°)

B-factors (Å2)

B-factor from Wilson plot (Å2)

Mean B-factor for main chain atoms (Å2)

Mean B-factor for side chain and water atoms (Å2)

Mean B-factor for all atoms(Å2)

Ramachandran's φ, ψ map

Residues in the most favoured regions (%)

Residues in the additionally allowed regions (%)

Residues in the generously allowed regions (%)

PDB ID


General Information	All patients	Participants	Unwilling participants

		Mainland China	Hong Kong	Hong Kong

Sex

Male	20 (47.62)	15 (50)	5 (41.67)	0 (0)


<underline>Month</underline>	<underline>Dietary recall since birth</underline>	<underline>24-hour dietary recall</underline>	<underline>Difference</underline>	<underline>Difference</underline>

	EBF	PBF	EBF	PBF	EBF	PBF

1	45	68	96	98	51	30

2	12	46	90	92	78	46

3	7	30	81	84	74	54

4	3	14	70	73	67	59

5	1	6	62	65	61	59

6	0	3	52	55	52	52

7		0	42	45		45

8			33	35

9			23	25

10			12	13

11			5	6

12			0	0

Month	24-hour dietary recall

	EBF	PBF

10	12	13

11	5	6

12	0	0


Outcome parameter	Instrument	Hypotheses	To be filled out by

Psychosocial functioning (inclusion criteria)	Global assessment of functioning[14]	II	Psychiatrist

Psychopathology	Brief Psychiatric Rating Scale (BPRS)[15]	II	Psychiatrist

Patient

Life satisfaction	11 point scale from the German Socioeconomic Panel[16]	II	Patient

Functional impairment	WHO-Disability Assessment Scale (WHO-DAS II)[17]	II	Patient

Substance misuse	Alcohol Use und Drug Use Scale (AUS, DUS)[18]	II	Patient

Medical adherence	Medical Adherence Rating Scale (MARS)[19]	II	Patient

Patient satisfaction with medical care1	Patient Assessment of Chronic Care (PACIC)[20]	III	Patient

Service use1,2	Client Sociodemographic and Service Receipt Inventory (CSSRI)[21]	I+IV	Practice assistant

Outcome parameter	Instrument	Hypotheses	To be filled out by

Service use1,2	Client Sociodemographic and Service Receipt Inventory (CSSRI)[21]	I+IV	Practice assistant


Groups	High fat diet a (%)	Others	Dietary energy contributions a(Kcal/100 g pellet)

Normal	0	100% normal rat pellet	335

High fat diet	50	50% normal rat pellet	548

50% Germinated brown rice	50	50% germinated brown rice	554

Low dose OE	100	100 mg/kg/day OE	554

High dose OE	100	200 mg/kg/day OE	554

Groups	High fat diet a (%)	Others	Dietary energy contributions a(Kcal/100 g pellet)

Norm	0	100%	335

al		 normal rat pellet

High fat diet	50	50% normal rat pellet	548

50% Germinated brown rice	50	50% germinated brown rice	554

Low dose OE	100	100 mg/kg/day OE	554

High dose OE	100	200 mg/kg/day OE	554


Characteristic	Number (percentage)a

Age group (in years)

15 – 29	2137 (48.4)

30 – 44	1475 (33.4)

45 – 59	808 (18.3)

Marital status

Never married	1267 (28.7)

Currently married	2671 (60.5)

Widow or divorcee	482 (10.9)

Place of residence

Rural	1864 (42.2)

Urban	2556 (57.8)

Religion

Christians	3096 (70.0)

Muslims	755 (17.1)

Others	569 (12.9)

Level of education

No school	540 (12.2)

Primary	1573 (35.6)

Secondary/higher	2306 (52.2)

Wealth index

Low	1456 (32.9)

Middle	1463 (33.1)

High	1501 (34.0)

Number of lifetime sex partners

0 – 5	1937 (43.8)

6 – 95	2473 (56.0)

Age at first sexual intercourse

≤ 17 years	2192 (49.6)

> 17 years	2215 (50.1)

Characteristic	Number (percentage)a

45 – 59	808 (18.3)

Marital status

Never married	1267 (28.7)

Currently married	2671 (60.5)

Widow or divorcee	482 (10.9)

Place of residence

Rural	1864 (42.2)

Urban	2556 (57.8)

Religion

Christians	3096 (70.0)

Muslims	755 (17.1)

Others	569 (12.9)

Level of education

No school	540 (12.2)

Primary	1573 (35.6)

Secondary/higher	2306 (52.2)

Wealth index

Low	1456 (32.9)

Middle	1463 (33.1)

High	1501 (34.0)

Number of lifetime sex partners

0 – 5	1937 (43.8)

6 – 95	2473 (56.0)

Age at first sexual intercourse

≤ 17 years	2192 (49.6)

> 17 years	2215 (50.1)


Risk factor/Preventive practice

Family history of osteoporosis

Female sex

Old age

Premature menopause

Smoking

Physical activity ( Weight bearing exercises)

Daily calcium requirement from food

Sources of calcium

Hormone therapy after menopause


Test	True positive (sensitivity)	False negative (1 − sensitivity)	True negative (specificity)	False positive (1 − specificity)	Total

Criteria	HPHPA > 101.5 mmol/mol creatinine

Control	 	 	61 (98.4%)	1 (1.6%)	62

ASDs	45 (72.6%)	17 (27.4%)	 	 	62

Criteria	3HPA > 45.2 mmol/mol creatinine

Control	 	 	62 (100%)	0 (0%)	62

ASDs	18 (29%)	44 (71%)	 	 	62

Criteria	3HHA > 14.8 mmol/mol creatinine

Control	 	 	60 (96.8%)	2 (3.2%)	62

ASDs	21 (33.9%)	41 (66.1%)	 	 	62

Criteria	Prediction probability > 0.65 (based on the three metabolites)

Control	 	 	98.4%	1.6%

ASDs	90.3%	9.7%


No. components in analysis	Best component(s)	Accuracy

One	H2BK5ac at TSS	0.72

Two	H2BK5ac at TSS-1	0.74

H2BK5ac at TSS-2

Three	H2BK5ac at TSS-1	0.75

H2BK5ac at TSS-2

No. components in analysis	Best component(s)	Accuracy

One	H2BK5ac at TSS	0.72

	H2	0.74

Two	BK5ac at TSS-1

H2BK5ac at TSS-2

Three	H2BK5ac at TSS-1	0.75

H2BK5ac at TSS-2


	Correlation coefficients

	EQ VAS score	EQ-5D index-G	EQ-5D index-UK

LSAS

_total score	-0.20*	-0.22*	-0.24*


		EDX

		positive	negative	total

Ultrasound	positive	13 (48.1)	4 (14.8)	17 (63.0)


Materials	E. coli (G−)	S. aureus (G+)	S. enterica (G−)	M. luteus (G+)	P. multocida (G−)	Cytospora sp.	P. piricola	F. oxysporum f. sp. cucumebrium

C3-3-2-2 a	0.46	- b	0.46	-	0.46	0.46	0.94	-

hurgadacin	0.46	3.75	0.94	>3.75	0.46	>3.75	0.94	>3.75


	MBBC predictions	Actual numbers

k-mer coverage	4.48	10.24	18.78	30	8.28	10.49	18.49


Category	N animals	Mean (l milk)	Std

Top sixth	16	39.7	9.3

Worse sixth	16	−29.0	5.2

Top twelfth	8	47.2	8.1

Worse twelfth	8	−32.5	5.5


Group	Case number (n)	TNF-α	IL-6

Before treatment	After treatment	Before treatment	After treatment

Treatment group	45	209.34±45.15	81.37±14.92	65.91±12.73	16.39±10.23

Contro	4		124.78	65.98±	34.28±13.0


	Prior beliefs

Postreading conclusions, n (%)	Appropriate	Inappropriate	Unsure	Total

Appropriate	163 (80.3%)	70 (47.0%)	62 (45.3%)	295 (60.4%)

Inappropriate	39 (19.2%)	74 (49.7%)	33 (24.1%)	146 (29.8%)


Characteristic	Confirmed HCV-InfectedRaw Frequency (n = 467)	Confirmed HCV-InfectedWeighted Mean (SD) or Proportion


Inflammatory reaction signs	SDE group	IRDE group

SS	SLE	RA	Total

Conjunctival congestion ratio	32.2%a	69.3%	78.5%	63.1%	70.3%a

Conjunctival papillary hyperplasia ratio	27.5%b	52.4%	61.8%	50.8%	55.0%b

Conjunctival follicular hyperplasia ratio	16.3%c	36.8%	40.4%	39.2%	38.8%c

Secretion ratio	12.6%d	10.1%	13.6%	10.6%	11.4%d

Inflammatory reaction signs	SDE group	IRDE group

SS

Conjunctival congestion ratio	32.2%a	69.3%

Conjunctival papillary hyperplasia ratio	27.5%b	52.4%

Conjunctival follicular hyperplasia ratio	16.3%c	36.8%

Secretion ratio	12.6%d	10.1%